Document:

EX-10.9

 Exhibit 10.9 

[***] Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be
competitively harmful if publicly disclosed. 
 Execution Version 

STOCK PURCHASE AGREEMENT 

STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of June 8, 2020, between The Trustees of Columbia
University in the City of New York, a New York corporation (“Columbia”), and Kures Inc., a Delaware corporation (the “Corporation”). 

A. Concurrently with the execution of this Agreement, Columbia is entering into an Exclusive License Agreement with the Corporation (the
“License Agreement”), pursuant to which Columbia is licensing the rights to certain technology to the Corporation. 

B. In partial consideration for the execution and delivery of the License Agreement by Columbia, the Corporation has agreed to issue to
Columbia certain shares of the Corporation’s capital stock in accordance with the terms and conditions of this Agreement. 
 C. In
consideration of the premises and the mutual representations, warranties, covenants and agreements contained in this Agreement, the parties to this Agreement agree as follows: 

SECTION 1. Sale of the Shares. 

1.1 Authorization of the Sale of Shares. The Corporation has authorized the issuance and sale to Columbia of (a) an
aggregate of [***] shares (the “Initial Shares”) of the Corporation’s common stock, 0.0001 par value (the “Common Stock”), representing 5% of the Common Stock on a Fully-Diluted Basis (as
hereinafter defined), and (b) such number of Funding Shares (as hereinafter defined and, together with the Initial Shares, the “Shares”) as may be issuable pursuant to Section 5.1, in each case at a price per share
equal to the fair market value of each such share, which price shall be deemed paid in partial consideration for the execution and delivery by Columbia of the License Agreement. 

1.2 Sale of the Initial Shares. Subject to the terms and conditions of this Agreement and in reliance upon the representations,
warranties and agreements contained herein, the Corporation will issue and sell to Columbia, and Columbia will purchase from the Corporation, at the Closing (as hereinafter defined) the Initial Shares. 

1.3 Closing. The closing of the purchase and sale of the Initial Shares (the “Closing”) shall be held as
promptly as practicable following the execution and delivery of this Agreement by e-mail exchange of signatures, or in such other manner as may be mutually agreed upon by the parties, upon a date (the
“Closing Date”) to be mutually agreed upon by the parties, and in any event within 10 days following the date hereof. 

SECTION 2. Representations and Warranties of the Corporation. The Corporation represents and warrants
to, and covenants and agrees with, Columbia as of the date of this Agreement and as of the Closing Date, as follows: 

 2.1 Organization and Good Standing. The Corporation is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to own and lease its properties, to carry on its business as presently conducted and as presently proposed
to be conducted and to execute, deliver and perform this Agreement and the License Agreement (collectively, the “Transaction Documents”), and to consummate the transactions contemplated by the Transaction Documents. True,
correct and complete copies of the Certificate of Incorporation and By-laws of the Corporation are annexed to this Agreement as Exhibit 2.1. The Corporation is authorized to do business and is in good
standing as a foreign corporation in each jurisdiction the laws of which require it to be so qualified. 
 2.2 Capitalization.

 (a) Authorized and Outstanding Shares. Immediately prior to consummation of the purchase and sale of the Initial Shares at
the Closing, (i) the authorized capital stock of the Corporation shall consist of [***] shares of Common Stock and [***] shares of Preferred Stock, par value $0.0001 per share, of which [***] and [***] shares of Common Stock and Preferred
Stock, respectively, shall be issued and outstanding, and (ii) all of such issued and outstanding shares will have been duly authorized, validly issued, fully paid and non-assessable. After giving effect
to the issuance of the Initial Shares, the Initial Shares will constitute 5% of the outstanding shares of Common Stock on a Fully-Diluted Basis. “Fully-Diluted Basis”
shall mean that the total number of outstanding shares of Common Stock shall be calculated to include, in addition to such outstanding shares and without double counting, (i) the shares of Common Stock issuable upon exercise, exchange and/or
conversion of all of the following securities (collectively, “Common Stock Equivalents”): all (A) securities convertible into or exchangeable for Common Stock, whether or not then convertible or exchangeable
(collectively, “Convertible Securities”); provided that convertible debt, SAFEs and other contractual rights and instruments (excluding preferred stock) or any portion thereof providing for the issuance of capital stock upon
conversion of, or otherwise in respect of, funds advanced and/or interest thereon (“Convertible Debt”) shall not be included within the term “Convertible Securities” until the earlier of the time that
(1) shares of capital stock or other Common Stock Equivalents of the Corporation have been issued or otherwise become effective in respect of such Convertible Debt, or portion thereof, and (2) the number of shares of capital stock of the
Corporation, and/or the number of other Common Stock Equivalents issuable or to become effective in respect of such Convertible Debt or portion thereof is or becomes a specific number of shares or share equivalents, (B) subscriptions, rights,
options and warrants to acquire shares of Common Stock, whether or not then exercisable (collectively, “Options”), and (C) securities convertible into or exchangeable or exercisable for Options or Convertible Securities
and any such underlying Options and/or Convertible Securities, in each case, whether or not then convertible, exchangeable and/or exercisable, and (ii) the maximum number of shares of Common Stock, whether in the form of such shares or Common
Stock Equivalents, issued, set aside, allocated or designated as issuable to management, employees or consultants of the Corporation pursuant to any stock option plan, restricted stock plan or otherwise (“Equity
Allocations”). The foregoing definitions of “Fully-Diluted Basis,” “Common Stock Equivalents,” “Convertible Securities,” “Convertible Debt,”
“Options,” and “Equity Allocations” shall also be deemed to include, on a Common Stock equivalent basis, all securities and rights that are economically similar to, or defined with reference to, capital stock or Common Stock
Equivalents (including, without limitation, any phantom stock, stock appreciation rights, restricted stock units or other such rights), in each case, whether or not then convertible, exchangeable and/or exercisable. 

  
 2 

 (b) Holders; Options. Schedule 2.2(b) annexed to this Agreement contains
a true, correct and complete list of (i) the holders of the issued and outstanding shares of capital stock of the Corporation, including the number, class and, if applicable, series, of the shares held by each such holder, and (ii) the
outstanding Common Stock Equivalents and each other contract, agreement, instrument, arrangement, understanding or proposed transaction pursuant to which the Corporation is or may become obligated to issue any shares of its capital stock, any Common
Stock Equivalents or other securities of the Corporation, including the number, class and, if applicable, series of such shares and/or other securities and the holders of such securities or other persons entitled to the benefit of any of the
foregoing. Except as provided in this Agreement or as listed on Schedule 2.2(b), (A) there is no preemptive right, anti-dilution right, right of first refusal, right of first offer, right of first negotiation or any other similar right of any
stockholder of the Corporation or other person or entity, to purchase or otherwise acquire securities of the Corporation, pursuant to any provision of law, the Certificate of Incorporation or By-laws of the
Corporation, any agreement to which the Corporation is a party, or otherwise (collectively, “Preemptive Rights”), (B) the issuance and sale of the Shares will not result in the creation of any restriction or Lien under any
contract, agreement, instrument, arrangement or understanding (including, without limitation, any proxy, voting agreement, voting trust, stockholders’ agreement, registration rights agreement, stock purchase agreement, investor rights
agreement, stock option plan, restricted stock plan or any similar arrangement) with respect to any capital stock or other securities of the Corporation (whether or not outstanding), except as described in the Certificate of Incorporation of the
Corporation or this Agreement, and (C) there is no judgment, order, writ, injunction or decree or law, rule or regulation (other than federal and state securities laws, rules and regulations) that restricts the transfer of the shares of capital
stock of the Corporation. As used in this Agreement, “Lien” shall mean any security interest, mortgage, pledge, lien, charge or other encumbrance. 

2.3 Authorization of Transaction Documents and the Shares. 

(a) Agreements. The execution, delivery and performance by the Corporation of, and the consummation by the Corporation of the
transactions contemplated by, the Transaction Documents have been duly authorized by all requisite corporate action by or on behalf of the Corporation, and each of the Transaction Documents constitutes a valid and binding obligation of the
Corporation, enforceable against the Corporation in accordance with its terms, except as limited by (i) applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or
affecting the enforcement of creditors’ rights generally, or (ii) laws relating to the availability of specific performance, injunctive relief, or other equitable remedies. 

(b) Shares. The offer, sale, issuance and delivery of the Shares have been duly authorized by all requisite corporate action by
or on behalf of the Corporation and when so issued, sold and delivered, the Shares will be validly issued, fully paid and nonassessable and not subject to any Preemptive Rights. 

  
 3 

 2.4 No Conflict. The execution, delivery and performance of, and the
consummation of the transactions contemplated by, the Transaction Documents, including, without limitation, the offer, sale, issuance and delivery of the Shares pursuant to this Agreement, have not resulted and will not result in (a) any
violation of, or default under, or conflict with, or constitute, with or without the passage of time and/or the giving of notice, any violation of, or default under or give rise to any right of termination, cancellation or acceleration under
(i) any term or provision of the Corporation’s Certificate of Incorporation or By-laws, (ii) any term or provision of any (A) contract, agreement, instrument, arrangement or understanding,
or (B) judgment, order, writ, injunction or decree of any court, government agency or any arbitrator, in each case, to which the Corporation is a party or by which it or its properties or assets are bound, or (iii) any statute, rule or
regulation applicable to the Corporation or its properties or assets, or (b) the creation of any Lien upon any of the properties or assets of the Corporation. 

2.5 Consents and Approvals. No consent, approval, waiver or authorization of, or designation, declaration or filing with, any
court, governmental authority or instrumentality or arbitrator or any other person or entity is required in connection with the valid execution, delivery and performance of, and the consummation of the transactions contemplated by, any of the
Transaction Documents by or on behalf of the Corporation, including, without limitation, the offer, sale, issuance or delivery of the Shares, except qualification of the offer and sale of the Shares under applicable federal and state securities or
blue sky laws, rules and regulations (or the filing of any notice or taking such action as may be necessary to secure an exemption from qualification, if available, under federal and state securities or blue sky laws), which qualifications, notice
filings and other action, if required, will be duly accomplished in a timely manner. 
 2.6 Offering. Subject to the accuracy
of Columbia’s representations in Section 3, the offer and sale of the Shares to be issued in conformity with the terms of this Agreement constitute transactions exempt from the registration requirements of Section 5 of the Securities
Act of 1933, as amended (the “Securities Act”), and the rules and regulations promulgated thereunder, and in compliance with all applicable state securities or blue sky laws, rules and regulations. 

2.7 Litigation. There is no action, suit, proceeding or investigation pending against the Corporation or its assets or properties
before any court, governmental agency or instrumentality or arbitrator (nor, to the Corporation’s knowledge, is there any basis for, or threat of, any of the foregoing). The Corporation is not a party or subject to the provisions of any
judgment, order, writ, injunction or decree of any court, government agency or instrumentality or arbitrator. There is no action, suit, proceeding or investigation by the Corporation currently pending or which the Corporation currently intends to
initiate. 
 2.8 Brokers or Finders. Columbia has not incurred, and will not incur, directly or indirectly, as a result of any
action taken by the Corporation, any liability for any brokerage or finder’s or agent’s fee or commission or any similar charges in connection with the Transaction Documents. 

2.9 Columbia Adverse Effect. 

(a) Columbia Adverse Effect. The Corporation acknowledges that Columbia has advised the Corporation that Columbia would not be
entering into this Agreement or any of the Transaction Documents if any of the following effects (each, a “Columbia Adverse Effect”) would arise out of the relationship between the Corporation and Columbia: any effect that is
(or if publicly disclosed would be) adverse or harmful to Columbia’s status or reputation or its relationships with the public, the community, governmental agencies or entities, its students, its faculty, its employees, its alumni, its trustees
or other constituencies. By way of illustration, but not limitation, the following would reasonably be expected to have a Columbia Adverse Effect: 

  
 4 

 (i) any past or present material violation of any law, rule or regulation, judgment, order,
writ, injunction or decree (including, without limitation, any violation constituting fraud, perjury, a breach of any securities law, rule or regulation or a breach of fiduciary duty) by a Related Party (as defined below) or by any person or entity
that was formerly a Related Party, if such violation by a former Related Party was in any way related to the Corporation, such person’s or entity’s relationship with the Corporation or such person’s or entity’s ownership of
securities of the Corporation; 
 (ii) any past or present material professional misconduct or malpractice by any Related Party or by any
person or entity that was formerly a Related Party, if such misconduct or malpractice by a former Related Party was in any way related to the Corporation, such person’s or entity’s relationship with the Corporation or such person’s or
entity’s ownership of securities of the Corporation; 
 (iii) any matter constituting a material breach by the Corporation of any of its
representations and warranties contained herein; or 
 (iv) any allegations as to any matter described in subsections (i), (ii) or
(iii) above. 
 (b) Related Party. For purposes of this Section 2.9, “Related Party” shall
mean the Corporation or any of the Corporation’s officers, directors, employees, stockholders or affiliates, including any person or entity that is an officer, director, employee, stockholder or affiliate after giving effect to the transactions
contemplated by this Agreement and the Transaction Documents (or any immediate family member of any such officer, director, individual stockholder or affiliate). 

(c) Disclosure. The Corporation has completely and accurately disclosed to Columbia any and all matters of which the Corporation
has knowledge as of the date of this Agreement (i) of the type described in subsections (a)(i), (a)(ii) or (a)(iv) above and (ii) which would reasonably be expected to have a Columbia Adverse Effect. 

2.10 Full Disclosure. No representation or warranty of the Corporation contained in any of the Transaction Documents (as
qualified by the schedules hereto) contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained herein or therein not misleading in light of the circumstances under which they were
made. 
 SECTION 3. Representations and Warranties of Columbia. Columbia represents and warrants to,
and covenants and agrees with, the Corporation, as of the date hereof and as of the Closing Date, as follows: 
 3.1 Investment
Intent. Columbia is acquiring the Shares for its own account, for investment and not with a view to the distribution thereof within the meaning of the Securities Act. 

  
 5 

 3.2 No Public Market. Columbia understands that the Shares have not been
registered or qualified under the Securities Act or any state securities laws, by reason of their issuance and sale in transactions exempt from the registration or qualification requirements of the Securities Act and applicable state securities
laws. Columbia acknowledges that reliance on said exemptions is predicated in part on the accuracy of Columbia’s representations and warranties contained in this Agreement. Columbia acknowledges and agrees that, subject to the other provisions
of this Agreement, (a) the Shares being acquired by it hereunder must be held by Columbia indefinitely unless a subsequent disposition of the Shares is registered or qualified under the Securities Act and applicable state securities laws or is
exempt from such registration or qualification, (b) there is no public market for the Shares, and (c) there can be no assurance that any such market will ever develop. 

3.3 Economic Risk. Columbia has no present need for liquidity in its investment in the Corporation and is able to bear the risk
of that investment for an indefinite period and to afford a complete loss of that investment. 
 3.4 Accredited Investor.
Columbia is an “accredited investor” as defined in Regulation D promulgated under the Securities Act. 
 3.5 Brokers or
Finders. The Corporation has not incurred, and will not incur, directly or indirectly, as a result of any action taken by Columbia, any liability for any brokerage, finder’s or agent’s fee or commission or any similar charges in
connection with the Transaction Documents. 
 SECTION 4. Conditions Precedent to Closing. 

4.1 Conditions Precedent to Closing by Columbia. The obligations of Columbia to purchase and pay for the Initial Shares at the
Closing are subject to the satisfaction of the following conditions on or prior to the Closing: 
 (a) Corporate Proceedings; Consents,
Etc. All corporate and other proceedings to be taken and all consents, approvals, waivers, authorizations, designations, declarations or filings to be obtained or made by or on behalf of the Corporation on or prior to the Closing in
connection with execution, delivery and performance of, and the consummation of the transactions contemplated by, the Transaction Documents shall have been taken or obtained and all documents relating to such matters shall be satisfactory in form
and substance to Columbia, which shall have received all such originals or certified or other copies of such documents as it may reasonably request. 

(b) Representations; No Breach. The representations and warranties of the Corporation contained in this Agreement shall be true
and correct on and as of the Closing as if made on such date, and the Corporation shall not have breached any of its representations, warranties, covenants or agreements contained in any of the Transaction Documents. 

(c) Blue Sky Matters. All notices, consents, approvals, qualifications and/or registrations required to be obtained or effected
under any applicable state securities or blue sky laws, rules and regulations in connection with the issuance, offer, sale and delivery of the Shares shall have been obtained or effected (except for the filing of any notice following the Closing or
in connection with any issuance of Funding Shares, as the case may be, which may be required following the Closing under applicable state securities or blue sky laws, rules and regulations, all of which will be duly and timely filed). 

  
 6 

 (d) Deliveries. The Corporation shall have delivered to Columbia (i) duly
executed counterparts of the License Agreement, together with any schedules and exhibits to such agreement, and any other Transaction Documents required to be executed and delivered on or prior to the Closing Date, (ii) a certificate of the
President or a Vice President of the Corporation as to (A) the Certificate of Incorporation and By-laws of the Corporation and resolutions of the Board of Directors of the Corporation with respect to the
Transaction Documents, and (B) the satisfaction of the conditions set forth in this Section 4, and (iii) a certificate of an executive officer or officers of the Corporation as to the incumbency of each officer of the Corporation
executing any of the Transaction Documents. 
 4.2 Conditions Precedent to Closing by the Corporation. The obligations of the
Corporation to issue and sell the Initial Shares at the Closing are subject to the satisfaction of the following conditions on or prior to the Closing: 

(a) Corporate Proceedings. The execution, delivery and performance by Columbia of, and the consummation by Columbia of the
transactions contemplated by, the Transaction Documents shall have been duly authorized by all requisite corporate action by or on behalf of Columbia. 

(b) Representations; No Breach. The representations and warranties of Columbia contained in this Agreement shall be true and
correct on and as of the Closing as if made on such date, and Columbia shall not have breached any of its representations, warranties, covenants or agreements contained in any of the Transaction Documents. 

(c) Deliveries. Columbia shall have delivered to the Corporation duly executed counterparts of the License Agreement, together
with any schedules and exhibits to such agreement, and any other Transaction Documents to which Columbia is a party and which are required to be executed and delivered on or prior to the Closing Date. 

SECTION 5. Anti-Dilution Rights. 

5.1 Funding Shares. 

(a) Issuance of Funding Shares. 

The Corporation shall, from time to time, issue to Columbia additional shares of Common Stock (the “Funding Shares”),
at a per share price equal to the then fair market value of each such share, which price shall be deemed to have been paid in partial consideration for the execution, delivery and performance by Columbia of the License Agreement, such that the
Common Stock held by Columbia (excluding any securities purchased pursuant to Section 5.2 or otherwise or issuable, directly or indirectly, in respect of any such purchased securities) shall equal [***]% of the Common Stock, on a Fully-Diluted
Basis, at all times up to and through the achievement of the Funding Threshold (as hereinafter defined). The “Funding Threshold” shall mean the time (following the date of this Agreement) at which the Corporation has
completed (i) 

  
 7 

 
the final closing of any series or subseries of its Series A Preferred Stock, whether pursuant to that certain Preferred Stock Purchase Agreement, dated August 28, 2019, by and among the
Corporation and the investors named therein, as the same may be amended or otherwise modified from time to time or otherwise (the “Purchase Agreement”), including, without limitation, the sale of the Corporation’s Series
A-2 Preferred Stock following the occurrence of the Series A-2 Milestone Events (as defined in the Purchase Agreement) in the amount set forth on Exhibit A-2 of the Purchase Agreement; or (ii) a financing or a series of related financings in which it has sold and issued shares of its capital stock with aggregate gross cash proceeds to the
Corporation of at least $[***], whichever of clause (i) or (ii) results in the issuance of a greater number (after adjusting for any capital changes) of Funding Shares to Columbia. For the avoidance of doubt, if clause (ii) of the
preceding sentence is applicable and the Corporation has issued and sold shares of its capital stock for gross cash proceeds in excess of the Funding Threshold, Funding Shares shall only be issued in respect of the issuance of shares (and Common
Stock Equivalents, if applicable) up to and through the Funding Threshold, and no Funding Shares shall be issued in respect of shares (and Common Stock Equivalents, if applicable) issued for gross proceeds in excess of the Funding Threshold. The
amount of any Convertible Debt (or any portion thereof) that is not included within the term Convertible Securities pursuant to Section 2.2(a) shall not be counted towards the Funding Threshold until such Convertible Debt (or portion thereof)
is included within the term Convertible Securities. With respect to the financing in which the Funding Threshold is exceeded, any shares or other Common Stock Equivalents issued upon conversion of or otherwise in respect of any such Convertible Debt
shall be deemed to have been issued prior to any other shares or other Common Stock Equivalents issued in such financing on a “first in first out” basis, based on the time that the initial funds were advanced in respect thereof. 

(b) Fractional Shares. The Corporation shall not issue fractional shares upon any issuance of the Funding Shares, but shall round
the number of Funding Shares to the nearest whole share. 
 (c) Payment of Taxes. The Corporation shall pay all stamp, transfer
and recording taxes and other similar governmental charges, if any, that are imposed in respect of the issuance, sale or delivery of the Funding Shares. The Corporation shall not be required, however, to pay any such tax or other charge imposed
solely as a result of any transfer involved in the issue of any certificate for Funding Shares in any name other than that of Columbia. 

(d) Documentation; Officer’s Certificates. Upon each issuance of Funding Shares hereunder, the Corporation (i) shall be
deemed to have remade, as of the date of, and after giving effect to, such issuance, the representations and warranties of the Corporation set forth in Sections 2.3, 2.4, 2.5 and 2.6 hereof; and (ii) shall furnish to Columbia (A) a
certificate representing such shares; and (B) a certificate of the President or a Vice President of the Corporation, dated the date of such issuance, stating that (1) such issuance is in full compliance with the provisions of this
Section 5.1; (2) no additional Funding Shares are required to be issued as of such date; and (3) the amount of the aggregate gross cash proceeds raised by the Corporation from the sale of capital stock as of such date. Promptly following
Columbia’s request, the Corporation shall furnish Columbia with such additional information as Columbia may reasonably request relating to any issuances of Common Stock and Common Stock Equivalents through the attainment of the Funding
Threshold, including, without limitation, capitalization schedules and copies of all agreements and other documentation relating to such issuances of Common Stock and Common Stock Equivalents. 

  
 8 

 5.2 Participation Rights. If the Corporation proposes to sell any equity
securities or securities or contractual rights that are convertible into equity securities of the Corporation (“New Securities”), then the Columbia and/or its Assignee (as defined below) will have the right to purchase up to
[***]% of the New Securities issued in each offering on the same terms and conditions as are offered to the others in each such financing. The Corporation shall provide Columbia, and any Assignee of which the Corporation has notice, with thirty
days’ advance written notice of each such financing, including reasonable detail regarding the terms and purchasers in the financing. The term “Assignee” means (a) any entity to which Columbia’s participation
rights under this Section 5.2 have been assigned either by Columbia or another entity, or (b) any entity that is controlled by Columbia. The participation rights in this Section 5.2 shall not be applicable to (i) Exempted
Securities (as defined in the Corporation’s Certificate of Incorporation, as may be amended and/or restated from time to time (the “Restated Certificate”); (ii) shares of Common Stock issued in the Corporation’s
first underwritten public offering of its Common Stock under the Securities Act (the “IPO”); and (iii) the issuance of Milestone Shares (as defined in the Purchase Agreement). Notwithstanding the foregoing, the
Corporation may elect to give notice to Columbia, and any Assignee of which the Corporation has notice, within thirty (30) days after the issuance of New Securities. Such notice shall describe the type, price and terms of the New Securities.
Columbia or, if applicable, its Assignee shall have twenty (20) days from the date notice is given to elect to purchase up to [***]% of such New Securities issued in such offering on the same terms and conditions as are offered to the others in
such financing. 
 5.3 Additional Interests. No additional shares of capital stock or other securities of the Corporation shall
be issued, sold or exchanged in any transaction covered by Section 5.1 unless and until the Corporation has complied with the applicable requirements of such Section. 

5.4 Termination of Rights. The rights under Section 5.2 shall terminate (i) immediately before the consummation of the
IPO, (ii) when the Corporation first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the
Restated Certificate. 
 SECTION 6. Other Covenants of the Corporation and Columbia. 

6.1 Interested Transactions. The Corporation shall not buy, sell or lease any property or assets from, borrow from or lend to, or
deal with or enter into any other transaction or agreement with any stockholder, officer or director, or any relative or affiliate of any of the foregoing, other than as approved by a majority of the disinterested directors of the Corporation and on
terms no less favorable to the Corporation than could be obtained in an arm’s-length transaction with an unaffiliated third party. 

  
 9 

 6.2 Financial Statements. The Corporation shall furnish to Columbia
(a) for each of the first three (3) quarters of the fiscal year, quarterly unaudited balance sheets and statements of income, stockholders’ equity and cash flows of the Corporation for such quarter and the portion of the
Corporation’s fiscal year then ended, setting forth the corresponding figures for such periods in the preceding year, if any, not later than 45 days after the end of each fiscal quarter, (b) annual unaudited financial statements, including
a balance sheet and statements of income, stockholders’ equity and cash flows not later than 90 days after the end of each fiscal year, and (c) from time to time upon Columbia’s request, such additional financial or other information
as Columbia may reasonably request. Any such financial statements shall be on a consolidated basis, if during the applicable reporting period the Corporation has any subsidiaries that are required to be consolidated with the Corporation for
financial reporting purposes. Notwithstanding the preceding provisions of this Section 6.2, the Corporation shall furnish such quarterly and annual financial statements to Columbia on any earlier date upon which they are made generally
available to the other stockholders of the Corporation, and the annual financial statements shall be audited, if audited financial statements are being provided to other parties. Notwithstanding anything else in this Section 6.2 to the
contrary, the Corporation may cease providing the information set forth in this Section 6.2 during the period starting with the date sixty (60) days before the Corporation’s good-faith estimate of the date of filing of a registration
statement if it reasonably concludes it must do so to comply with the Commission rules applicable to such registration statement and related offering; provided that the Corporation’s covenants under this Section 6.2 shall be reinstated at
such time as the Corporation is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. The covenants set forth in this Section 6.2 and in Sections 6.3 and 6.4 shall
terminate and be of no further force or effect (i) immediately before the consummation of the IPO, (ii) when the Corporation first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act,
or (iii) upon the closing of a Deemed Liquidation Event, as such term is defined in the Restated Charter, whichever event occurs first. 

6.3 Other Information. The Corporation shall deliver to Columbia promptly after the occurrence of any such event, written notice
and a description of any default or other event, including any litigation, which would reasonably be expected to have a material adverse effect upon the Corporation, its financial condition, results of operations or business. 

6.4 Books and Records; Inspection. The Corporation shall keep complete records and books of account and report under all terms
and provisions of this Agreement in accordance with GAAP. At any time and from time to time, during regular business hours, the Corporation shall permit representatives of Columbia to examine and make copies of its records and books of account, to
inspect its properties and to discuss its affairs with its officers, directors and independent accountants; provided, however, that the Corporation shall not be obligated pursuant to this Section 6.4 to provide access to any information the
disclosure of which would adversely affect the attorney-client privilege between the Corporation and its counsel. 
 6.5 Corporate
Existence; No Impairment. The Corporation shall maintain the Corporation’s corporate existence and any material qualifications to do business in any jurisdiction. The Corporation shall not, by amendment of its Certificate of
Incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other action, avoid or seek to avoid the observance or performance of any of the terms and provisions to be
observed or performed by it pursuant to this Agreement, but will at all times in good faith assist in the carrying out of all of such terms or provisions and in the taking of all such action as may be necessary or appropriate in order to protect the
rights of Columbia under this Agreement against impairment. Notwithstanding the foregoing, nothing in this Section 6.5 shall prevent the Corporation from consummating a Deemed Liquidation Event, as such term is defined in the Restated
Certificate. 

  
 10 

 6.6 Rule 144 Compliance. With a view to making available the benefits of
certain rules and regulations of the Securities and Exchange Commission (the “Commission”) which may at any time permit the sale of the shares to the public without registration, 90 days after any registration statement
covering a public offering of securities of the Corporation under the Securities Act shall have become effective and at all times thereafter when either the requirements of Rule 144(c)(1) are applicable to any of the Shares or the Corporation is not
a reporting issuer described in Rule 144(c)(1), the Corporation agrees to: (a) make and keep public information available, as those terms are understood and defined in Rule 144 under the Securities Act; (b) use its best efforts to file
with the Commission in a timely manner all reports and other documents required of the Corporation under the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”); (c) furnish to each holder
of the Shares forthwith upon request a written statement by the Corporation as to Corporation’s compliance with the reporting requirements of Rule 144 and of the Securities Act and the Exchange Act, and such other reports and documents so filed
by the Corporation as such holder may reasonably request in availing itself of any rule or regulation of the Commission allowing such holder to sell any Shares without registration; and (d) use the Corporation’s best efforts to satisfy the
requirements of all such rules and regulations (including the requirements for current public information, registration under the Exchange Act and timely reporting to the Commission) at the earliest possible date after its first registered public
offering. 
 6.7 Board Observer. Until the Funding Threshold has been attained, Columbia shall have the right, but not the
obligation, from time to time to designate one individual (the “Board Observer”) who may attend and otherwise participate in (including, without limitation, by telephonic or internet conference) all meetings of the Board of
Directors of the Corporation and committees thereof in a non-voting observer capacity, and the Corporation shall, upon request, provide the Board Observer copies of all notices, minutes, consents, and other
materials that it provides to its directors (or committee members) with respect to such meetings at the same time as provided to such directors (or committee members); provided, however, that such representative shall agree to hold in confidence all
information so provided; and provided further, that the Corporation reserves the right to withhold any information and to exclude such representative from any meeting or portion thereof if access to such information or attendance at such meeting
could adversely affect the attorney-client privilege between the Corporation and its counsel or result in a conflict of interest. The Board Observer may, at his or her election, participate fully in discussions of matters brought to the Board of
Directors or committees thereof. The intent of this Section 6.7 is to provide the Board Observer with all participation rights of directors (or committee members), other than the right to vote on matters brought before the Board of Directors of
the Corporation or committees thereof. Columbia shall notify the Corporation as to the identity of the initial Board Observer and from time to time as to any Board Observer’s ceasing to serve in such capacity (which shall be in Columbia’s
sole discretion) and as to the identity of any replacement for any previously designated Board Observer. 

  
 11 

 6.8 Co-Sale Rights. Columbia shall
have the co-sale rights set forth in Section 2.2 of that certain Right of First Refusal and Co-Sale Agreement, dated August 28, 2019, by and among the
Corporation and the investors and key holders named therein, as may be amended and/or restated from time to time (the “Co-Sale Agreement”) as if Columbia were a Major Investor (as
defined in the Co-Sale Agreement). For the avoidance of doubt, the rights set forth in this Section 6.8 shall terminate and be of no further force or effect at the same time such rights terminate pursuant
to the terms of the Co-Sale Agreement. 
 6.9 Stock Certificate. The Corporation shall
deliver to Columbia a stock certificate representing the Initial Shares promptly following the Closing. 
 6.10
Confidentiality. Columbia agrees that it will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Corporation) any confidential information obtained from the Corporation
pursuant to the terms of this Agreement (including notice of the Corporation’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result
of a breach of this Section 6.10 by Columbia), (b) is or has been independently developed or conceived by Columbia without use of the Corporation’s confidential information, or (c) is or has been made known or disclosed to Columbia by
a third party without a breach of any obligation of confidentiality such third party may have to the Corporation; provided, however, that Columbia may disclose confidential information (i) to its attorneys, accountants, consultants, and other
professionals to the extent necessary to obtain their services in connection with monitoring its investment in, and licensing arrangements with, the Corporation; (ii) to any Affiliate of Columbia or any Assignee in the ordinary course of
business, provided that Columbia informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iii) as may otherwise be required by law, regulation, rule, court order
or subpoena, provided that Columbia, if permitted by law, promptly notifies the Corporation of such disclosure and takes reasonable steps, which shall not involve more than nominal expenditures by Columbia, to minimize the extent of any such
required disclosure. 
 6.11 “Market Stand-off” Agreement. Columbia agrees
that it will not, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the IPO and ending on the date specified by the Corporation and the managing underwriter
(such period not to exceed one hundred eighty (180) days), or such other period as may be requested by the Corporation or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research
reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2241, or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any
option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or
exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for the IPO or (ii) enter into any swap or other arrangement that transfers to another, in whole or
in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing
provisions of this Section 6.11 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, and shall be applicable to the holder of the Shares only if all officers, directors and holders of more than one
percent (1%) of the outstanding Common Stock (after giving effect to the conversion into Common Stock of all outstanding Preferred Stock) enter into 

  
 12 

 similar agreements. The underwriters in connection with the IPO are intended third party beneficiaries of
this Section 6.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each holder of the Shares further agrees to execute such agreements in customary form as may be reasonably
requested by the underwriters in the IPO that are consistent with this Section 6.11 or that are necessary to give further effect thereto. 

SECTION 7. Restrictions on Transfer. 

7.1 Legend. Each certificate for the Shares and any shares of capital stock received in respect of the Shares, whether by reason
of a stock split or share reclassification, a stock dividend on the Shares or otherwise, and each certificate for any such securities issued to subsequent transferees of any such certificate shall (unless otherwise permitted by law) be stamped or
otherwise imprinted with a legend in substantially the following form: 
 “THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN
ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THESE SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN EXEMPTION THEREFROM UNDER SAID ACT.” 

7.2 Restrictions on Transfer. None of the Shares shall be sold, assigned, pledged, hypothecated or otherwise transferred or
disposed of unless and until one of the following events shall have occurred: 
 (a) Compliance with the Securities Act. The
Shares are transferred pursuant to and in conformity with Rule 144 (or any successor rule) or an effective registration statement filed with the Commission pursuant to the Securities Act or if, in the opinion (reasonably acceptable to the
Corporation) of counsel to the holder of the Shares, such transfer or disposition is pursuant to a valid exemption from registration under the Securities Act; or 

(b) Certain Transfers. The Shares are transferred to an affiliate of the transferor or a trust controlled by or for the benefit
of the transferor or any affiliate of the transferor or any venture fund, hedge fund or similar fund managed or funded, in whole or in part, by transferor or any such affiliate or trust or in which transferor or any such affiliate or trust holds an
interest (each, a “Permitted Transferee”) and such Permitted Transferee has delivered to the Corporation a written agreement making the representations and warranties set forth in Sections 3.1, 3.2, 3.3 and 3.4 and
agreeing to be bound by the restrictions of this Section 7 with respect to the Shares so transferred. 
 7.3 Removal of
Legend. Notwithstanding anything herein to the contrary, the restrictions imposed by this Section 7 on the transferability of any Shares shall cease and terminate as to any such Shares when such Shares are sold or otherwise disposed of
(a) in compliance with Rule 144(b)(1) promulgated by the Commission under the Securities Act (or any successor rules); or (b) in accordance with the intended method of disposition set forth in a registration statement or such other method
that does not require that the securities transferred bear the legend set forth 

  
 13 

 
in Section 7.1 hereof. Whenever the restrictions imposed by this Section 7 have terminated as described in the immediately preceding sentence or (in the opinion, reasonably acceptable
to the Corporation, of counsel to the holder of the Shares) have otherwise terminated, a holder of a certificate for such Shares as to which such restrictions have terminated shall be entitled to receive from the Corporation, without expense, as
soon as practicable (and, in any event, no later than 10 days following such termination or delivery of such opinion to the Corporation, as the case may be), a new certificate not bearing the restrictive legend set forth in Section 7.1
hereof and not containing any other reference to the restrictions imposed by this Agreement. 
 SECTION 8.
Survival. All representations and warranties shall survive the Closing indefinitely. All statements contained in a certificate or other instrument delivered by the Corporation pursuant to this Agreement in connection with the
transactions contemplated by this Agreement shall constitute representations and warranties by the Corporation under this Agreement. All agreements contained herein shall survive indefinitely until, by their respective terms, they are no longer
operative. 
 SECTION 9. Miscellaneous. 

9.1 Remedies. In case any one or more of the covenants or agreements set forth in this Agreement shall have been breached by any
party, the other party may proceed to protect and enforce its rights either by suit in equity by action at law, including, but not limited to, an action for damages as a result of any such breach and/or an action for specific performance of any such
covenant or agreement contained in this Agreement. 
 9.2 Successors and Assigns. This Agreement, and each of the provisions
hereof, shall be binding upon, and inure to the benefit of, the Corporation and Columbia and their respective successors and assigns as to this Agreement or any such provision, including, without limitation, any Assignee. 

9.3 Entire Agreement. This Agreement (including the schedules and exhibits to this Agreement) and other writings delivered
pursuant to this Agreement or which form a part of this Agreement contain the entire agreement between the parties with respect to the subject matter of this Agreement and supersede all prior and contemporaneous arrangements or understandings with
respect to such subject matter. 
 9.4 Notices. All notices, requests, consents and other communications to be given, delivered
or otherwise made hereunder to any party shall be deemed to be sufficient if contained in a written instrument delivered in person, by overnight courier, or duly sent by first class registered or certified mail, postage prepaid, addressed to such
party to the address set forth below or such other address as may hereafter be designated in writing by either party by notice to the other: 

  
 14 

 (a) If to the Corporation, to: 

9 Fairlawn Avenue 
 Dobbs Ferry,
New York 10522 
 Attn: Chief Executive Officer 

with a copy to: 
 Goodwin
Procter LLP 
 620 Eighth Avenue 

New York, NY 10018 
 Attention:
[***] 
 (b) If to Columbia, to: 

Executive Director 
 Columbia
Technology Ventures 
 80 Claremont Ave. #4F 

Mail Code 9606 
 New York, NY
10027-5712 
 with a copy to: 

Office of the General Counsel 

Columbia University 
 412 Low
Memorial Library 
 535 West 116th Street, Mailcode 4308 

New York, NY 10027 
 All such notices and other
communications shall be deemed to have been received on the date of delivery. 
 9.5 Changes. The terms and provisions of this
Agreement may not be modified or amended, or any of the provisions hereof waived, temporarily or permanently, except with the written consent of the Corporation and Columbia. 

9.6 No Waiver. No waiver of any breach, term or condition of this Agreement shall be deemed to be a waiver of any other or
subsequent breach, term or condition, whether of like or different nature. 
 9.7 Severability. If any provision of this
Agreement is held to be invalid or unenforceable under applicable law by a court of competent jurisdiction, such invalidity or unenforceability shall not affect the validity or enforceability of such provision in any other jurisdiction or the
validity or enforceability of the remaining provisions of this Agreement, subject to the following provisions of this Section 9.7. Subject to the discretion of such court, any invalid or unenforceable provision shall be reformed, amended and
limited to the extent necessary to render such provision, as so reformed, amend and limited, valid and enforceable or, if such a reformation would not give effect to the original intention of the parties and the intended economic effect of such
unenforceable provision, this Agreement (including any remaining provisions hereof) shall be reformed by such court in such a manner as may be necessary or advisable in order to give effect to the original intention of the parties and the intended
economic effect of such unenforceable provision. If any such court declines to so reform this Agreement, the parties agree to renegotiate this Agreement in good faith so as to give effect to the original intention of the parties and the intended
economic effect of such unenforceable provision. 

  
 15 

 9.8 Counterparts. This Agreement may be executed in any number of
counterparts, and each such counterpart hereof shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement. 

9.9 Headings. The headings of the various sections of this Agreement have been inserted for convenience of reference only
and shall not be deemed to be part of this Agreement. 
 9.10 Construction. Except as the context may otherwise require, any
pronouns used herein shall include the corresponding masculine, feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. References to sections, schedules, and exhibits shall, unless otherwise
specified, refer to the sections of, and the schedules and exhibits to, this Agreement. References to any agreement or document are to such agreement or document as amended, supplemented or otherwise modified from time to time. 

9.11 Governing Law. This Agreement shall be governed by New York law applicable to agreements made and to be fully performed in
the State of New York. The parties agree that any and all claims arising under this Agreement or relating thereto shall be heard and determined exclusively in the United States District Court for the Southern District of New York or in the courts of
the State of New York located in the City and County of New York, and the parties agree to submit themselves to the personal jurisdiction of those courts and not to raise any objection to venue being had in those courts. 

[THE REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK.] 
  

  
 16 

 IN WITNESS WHEREOF, the undersigned have duly executed this Agreement as of the date
first above written. 
  

							
	COLUMBIA:	 	 THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

				
		 		 	By:	 	 /s/ Orin Herskowitz

		 		 		 	Name: Orin Herskowitz
		 		 		 	Title: Exec Dir, CTV
		
	CORPORATION:	 	 KURES INC.

				
		 		 	By:	 	 /s/ Srinivas Rao

		 		 		 	Name: Srinivas Rao
		 		 		 	Title: Chief Executive Officer

 Each of the undersigned hereby consents to, and agrees (on its own behalf and on behalf of its direct or indirect transferees)
to be bound by the provisions of Section 6.8 of the foregoing Agreement: 
 KEY HOLDERS: 

 

	
	 /s/ Errol de Souza

	Name: Errol de Souza
	
	 /s/ Andrew Kruegel

	Name: Andrew Kruegel
	
	 /s/ Dalibor Sames

	Name: Dalibor Sames

 [Signature Page to Stock Purchase Agreement] 

 
			
	SAMUEL E. JAVITCH GST TRUST
		
	By:	 	 /s/ Peter Lebovitz

	Name:	 	Peter Lebovitz
	Title:	 	Trustee
	
	JAVITCH 2018 TRUST
		
	By:	 	 /s/ Peter Lebovitz

	Name:	 	Peter Lebovitz
	Title:	 	Trustee
	
	HEN FAMILY GST TRUST
		
	By:	 	 /s/ Elizabeth Isaacson

	Name:	 	Elizabeth Isaacson
	Title:	 	Trustee
	
	HEN 2018 TRUST
		
	By:	 	 /s/ Elizabeth Isaacson

	Name:	 	Elizabeth Isaacson
	Title:	 	Trustee

 [Signature Page to Stock Purchase Agreement]EX-10.10

 Exhibit 10.10 

[***] Certain information in this document has been omitted from this exhibit because it is both 

(i) not material and (ii) would be competitively harmful if publicly disclosed. 

EXCLUSIVE LICENSE AGREEMENT 
  

 
 This Agreement is dated
6/8, 2020 (the “Effective Date”), and is between THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, a New York corporation (“Columbia”), and KURES, INC., a Delaware corporation (the
“Company”). Columbia and Company agree as follows: 
  

	1.	 Definitions. In this Agreement, the following definitions apply: 

a.    “Affiliate” means any corporation or other entity that directly or indirectly controls, is
controlled by, or is under common control with, another corporation or entity. Control means direct or indirect ownership of, or other beneficial interest in, fifty percent (50%) or more of the voting stock, other voting interest, or income of a
corporation or other entity. 
 b.    “Change of Control” means any transaction or event or multiple
transactions or events (including, without limitation, a merger, other business combination, share exchange, spin-off, liquidation or reorganization) as a result of which all or substantially all of the
Company’s assets are sold, leased, licensed or otherwise transferred or a change of control shall occur or if there is an initial public offering of any securities of the Company. Notwithstanding the foregoing, the term “Change of
Control” will not include any sale of shares of capital stock of Company, in a single transaction or series of related transactions in which Company issues new securities to institutional investors for cash or the cancellation or conversion
of indebtedness or a combination thereof where such transaction(s) are conducted primarily for bona fide equity financing purposes. 

c.    “Cover” or “Covered By” means (i) infringes, in the case of a Valid Claim in
an issued patent, or (ii) would infringe the Valid Claim if it existed in an issued patent, in the case of a Valid Claim in a pending application. 

d.    “Designee” means a corporation or other entity that is employed by, under contract to, or in
partnership with (i) Company, (ii) a Sublicensee, (iii) an Affiliate of Company or (iv) an Affiliate of a Sublicensee, wherein such corporation or other entity is granted the right to make, use, sell, promote, distribute, market,
import, or export Products. 
 e.    “Field” means all uses and applications. 

f.    “Initiation” shall mean, with respect to a human clinical trial, the dosing of the first patient in
such trial. 
 g.    “License Year” means the one-year period
from the Effective Date of this Agreement or an anniversary thereof to the next anniversary of the Effective Date. 

h.    “Materials” means the tangible physical material, if any, developed prior to the Effective Date by
or under the direction of [***] and provided to or received by Company hereunder (including any Materials conveyed to the Company after the Effective Date) and listed in Exhibits A1 and A2 hereto, which will be amended if Materials are provided
to the Company after the Effective Date. 

 i.    “Mitragynine Patent” or
“Mitragynine Patents” means the following: (i) the United States and foreign patents and/or patent applications listed in Exhibit A2 hereto; (ii) any non-provisional patent
applications that claim priority to any provisional patent applications listed in Exhibit A2 hereto; (iii) any and all claims of continuation-in-part
applications that claim priority to the United States patent applications listed in Exhibit A2, but only where such claims are directed to inventions disclosed in the manner provided in the first paragraph of 35 U.S.C. Section 112 in the
United States patent applications listed in Exhibit A2, and such claims in any patents issuing from such continuation-in-part applications; (iv) any and all
foreign patent applications, foreign patents or related foreign patent documents that claim priority to the patents and/or patent applications listed in Exhibit A2; (v) any and all divisionals, continuations, reissues, re-examinations, renewals, substitutions, and extensions of the foregoing; and (vi) any and all patents issuing from the foregoing. Notwithstanding the preceding definition, Patent and Patents will not include
any patents or patent applications based on research conducted after the Effective Date, except as otherwise agreed in a separate writing. 

j.    “Mitragynine Products” means Patent Products Covered By a Mitragynine Patent and Other
Products that use or incorporate, in whole or in part, Mitragynine Technical Information. 
 k.    “Mitragynine
Technical Information” means any know-how, technical information and data developed by Columbia by or under the direction of [***] or individuals under their direction before the Effective Date
and provided to or received by Company, which know-how, technical information and data are necessary or useful for the discovery, development, manufacture, use, sale, offering for sale, importation,
exportation, distribution, rental or lease of a Product, including, without limitation, (i) any know-how, technical information and data disclosed in any Patent or (ii) any reports or disclosures
concerning research or inventions provided or disclosed to, or otherwise received by, Company. Technical Information will include, but is not limited to, the information in Exhibit A2 hereto. 

l.    “NDA” shall mean a New Drug Application (as described in 21 C.F.R. § 314) that is
submitted to the U.S. Food and Drug Administration (“FDA”) to propose that the FDA approve a new pharmaceutical for sale and marketing in the U.S. 

m.    “Net Sales” means the greater of the gross invoice or contract price charged to Third Party
customers by the Company, a Sublicensee or any Designee or Affiliate of the foregoing for the Product or the actual consideration paid to the Company, a Sublicensee or any Designee or Affiliate of the foregoing by Third Party customers for the
Product. For all Products used or consumed by any Third Party, Company may deduct [***] from Net Sales and shall not deduct taxes, shipping charges, allowances, and the like before calculating royalties due. The intent of this definition of
Net Sales is to allow Columbia to derive a royalty on the end sale of a Product to the first Third Party. 

  
 2 

 In the case of transfers of Products between any of Company, Sublicensees, Designees, and
Affiliates of any of the foregoing, for subsequent sale, rental, lease or other transfer of such Products to Third Parties, Net Sales will be the gross invoice or contract price charged to the Third Party customer for that Product in an arm’s-length transaction. Company may deduct [***] from Net Sales and shall not deduct taxes, shipping charges, allowances, and the like before calculating royalties due. 

Solely for purposes of calculating Net Sales, if Company or its Affiliates or any Sublicensee or Designee sells a Patent Product in the form
of a combination product that contains a Patent Product and one or more other therapeutically or prophylactically active ingredients that are not a Patent Product (“Other Compound”) (whether combined in a single formulation or
package, as applicable, or formulated separately but packaged under a single label approved by a Regulatory Authority and sold together for a single price) (such combination product, a “Combination Product”), Net Sales of such
Combination Product for the purpose of determining the payments due to Columbia pursuant to this Agreement will be calculated by multiplying actual Net Sales of such Combination Product as determined in the first paragraph of the definition of
“Net Sales” by the fraction A/(A+B) where A is the gross selling price of such Patent Product that does not contain such Other Compound in such country and B is the gross selling price of the Other Compound in such country when sold
separately, in each case, during the relevant period. If the gross selling price of such Patent Product in such country when sold separately in finished form (i.e., without the Other Compound) can be determined but the gross selling price of the
Other Compound in such country cannot be determined, Net Sales in such country for purposes of determining royalty payments will be calculated by multiplying the actual Net Sales of the Combination Product in such country by the fraction A / C where
A is the gross selling price of such Patent Product that does not contain such Other Compound in such country when sold separately during the relevant period, and C is the gross selling price of the Combination Product in such country. If such
separate sales are not made in a country, Net Sales will be calculated by multiplying the actual Net Sales of the Combination Product in such country by a fraction fairly and reasonably reflecting the relative value contributed by the relevant
Patent Product (without the Other Compound) to the total value of the Combination Product as determined by the Parties in good faith. For clarity, pharmaceutical dosage form vehicles, delivery devices, adjuvants and excipients shall be deemed not to
be “active ingredients.” 
 n.    “Other Product” means any product or service (or component
thereof), other than a Patent Product, the discovery, development, manufacture, use, sale, offering for sale, importation, exportation, distribution, rental or lease of which involves the direct use of or incorporation, in whole or in part, of
Materials or Technical Information. 
 o.    “Patent” or “Patents” means the
Tianeptine Patents and the Mitragynine Patents. 
 p.    “Patent Product” means any product or service
(or component thereof) the discovery, development, manufacture, use, sale, offering for sale, importation, exportation, distribution, rental or lease of which is Covered By a Valid Claim of a Patent. 

q.    “Phase I” means, with respect to a clinical trial conducted pursuant to an IND, any controlled
human clinical trial conducted in the United States as required under and pursuant to 21 C.F.R. §312.21(a), or, with respect to a jurisdiction other than the United States, a similar clinical study. 

  
 3 

 r.    “Phase II” means, with respect to a clinical
trial conducted pursuant to an IND, any controlled human clinical trial conducted in the United States as required under and pursuant to 21 C.F.R. §312.21(b), or, with respect to a jurisdiction other than the United States, a similar clinical
study. 
 s.    “Phase III” means, with respect to a clinical trial conducted pursuant to an IND, any
controlled human clinical trial conducted in the United States as required under and pursuant to 21 C.F.R. §312.21(c), or, with respect to a jurisdiction other than the United States, a similar clinical study. 

t.    “Product” or “Products” means a Patent Product and/or an Other Product. 

u.    “Sublicensee” means any third party to whom Company has granted a sublicense under the licenses
granted to it pursuant to Section 2(a) (through one or more tiers). For clarity, any third parties to whom a Sublicensee has granted a sublicense under the sublicense granted to it by the Company or another Sublicensee shall be considered a
“Sublicensee” hereunder. Additionally, (a) an Affiliate of Company or a Designee exercising rights hereunder, (b) any acquirer of, or successor to, Company in connection with a Change of Control or (c) any assignee of
this Agreement by Company upon an assignment of this Agreement by Company in accordance with Section 18, in each case ((a)-(c)), shall not be considered a Sublicensee; provided that, with respect to the foregoing (b) and (c), Company does
not otherwise grant a sublicense to such entity. 
 v.    “Technical Information” means the Tianeptine
Technical Information and the Mitragynine Technical Information. 
 w.    “Territory” means worldwide.

 x.    “Third Party” means any entity or person other than Columbia, the Company, Sublicensees,
Designees, or their respective Affiliates. 
 y.    “Third Party Generic Competition” means, with
respect to a particular Product in a country, a product that (i) contains the same active pharmaceutical ingredient, in any physical or salt form, as such Product, (ii) is bioequivalent to such Product, as determined under a regulatory
approval for such product granted or approved (including through the abbreviated approval pathways as set forth in sections 505(j) and 505(b)(2) of the FD&C Act (21 U.S.C. 355(j) and 21 U.S.C. 355(b)(2), respectively)), (iii) may be legally
substituted by pharmacies in such country for such Product when filling a prescription written therefor without having to seek authorization to do so from the physician or other health care provider writing such prescription, and (iv) is
legally marketed and sold in such country by a Third Party. 
 z.    “Tianeptine Patent” or
“Tianeptine Patents” means the following: (i) the United States and foreign patents and/or patent applications listed in Exhibit A1 hereto; (ii) any non-provisional patent
applications that claim priority to any provisional patent applications listed in Exhibit A1 hereto; (iii) any and all claims of continuation-in-part
applications that claim priority to the United States patent applications listed in Exhibit A1, but only where such claims are directed to inventions disclosed in the manner provided in the first paragraph of 35 U.S.C. Section 112 in the
United States patent applications listed in Exhibit A1, and such claims in any 

  
 4 

 
patents issuing from such continuation-in-part applications; (iv) any and all foreign patent applications,
foreign patents or related foreign patent documents that claim priority to the patents and/or patent applications listed in Exhibit A1; (v) any and all divisionals, continuations, reissues,
re-examinations, renewals, substitutions, and extensions of the foregoing; and (vi) any and all patents issuing from the foregoing. Notwithstanding the preceding definition, Patent and Patents will not
include any patents or patent applications based on research conducted after the Effective Date, except as otherwise agreed in a separate writing. 

aa.    “Tianeptine Products” means Patent Products Covered By a Tianeptine Patent and Other
Products that use or incorporate, in whole or in part, Tianeptine Technical Information. 
 bb.    “Tianeptine
Technical Information” means any know-how, technical information and data developed by Columbia by or under the direction of [***] or individuals under their direction before the Effective Date and
provided to or received by Company, which know-how, technical information and data are necessary or useful for the discovery, development, manufacture, use, sale, offering for sale, importation, exportation,
distribution, rental or lease of a Product, including, without limitation, (i) any know-how, technical information and data disclosed in any Patent or (ii) any reports or disclosures concerning
research or inventions provided or disclosed to, or otherwise received by, Company. Technical Information will include, but is not limited to, the information in Exhibit A1 hereto. 

cc.    “Valid Claim” means (a) a claim of an issued and unexpired patent which has not been revoked
or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through
reissue or disclaimer or otherwise or (b) a pending claim of a pending patent application, which application (i) has not been pending for longer than [***] years from the first substantive office action in such application or longer than
[***] from the earliest priority filing date for the claim, whichever is longer, and (ii) has not been abandoned or finally rejected without the possibility of appeal or refiling or without such appeal having been taken or refiling having been
made within the applicable time periods. 
  

	2.	 License Grant. 

a.    Columbia hereby grants the Company and any Affiliate and Designees thereof, upon and subject to all the terms of this
Agreement (including Section 3), the following: 
 i.    an exclusive license under the Patents to discover,
develop, manufacture, have made, use, sell, offer to sell, have sold, import, export, distribute, rent or lease Products in the Field and throughout the Territory; and 

ii.    an exclusive license under the Materials and Technical Information to discover, develop, manufacture, have made,
use, sell, offer to sell, have sold, import, export, distribute, rent or lease Products in the Field and throughout the Territory; provided that such license to Technical Information shall automatically convert to a
non-exclusive license upon the publication or other public distribution of Technical Information and provided further that Columbia and its faculty and employees shall have the right to publish, disseminate or
otherwise disclose the Technical Information. 

  
 5 

 Columbia shall transfer to the Company such Materials and Technical Information within thirty (30) days
of the Effective Date (in each case, to the extent such Materials and Technical Information are available and have not already been provided to Company). 

b.    Columbia hereby grants Company and its Affiliates and Designees the right to grant sublicenses (through multiple
tiers) under the licenses granted in Section 2a on the following conditions: (i) the Sublicensee, which shall include all further multiple tier Sublicensees, agrees to abide by and be subject to all the terms of this Agreement that apply
to such Sublicensee; (ii) if any Sublicensee (or any of its Affiliates) initiates any proceeding or otherwise asserts any claim challenging the validity or enforceability of any Patent in any court, administrative agency or any other forum,
Company shall, upon written request by Columbia, forthwith terminate the sublicense agreement with such Sublicensee, and the sublicense agreement shall provide for such right of termination by Company; (iii) the sublicense agreement provides
that, in the event of any inconsistency between the sublicense agreement and this Agreement, this Agreement controls; (iv) the Sublicensee is obligated to submit [***] reports to Company consistent with the reporting provision of
Section 5a herein; (v) Company remains fully liable for the performance of its and its Sublicensee’s obligations to Columbia hereunder; (vi) Company notifies Columbia of any grant of a sublicense, either by Company or a
Sublicensee, and provides to Columbia, upon request, a copy of any executed sublicense agreement (subject to reasonable redaction) within [***] days following execution of the sublicense; and (vii) no such sublicense relieves Company of its
obligations under Section 6 to exercise its own commercially reasonable efforts, directly or through a sublicense, to discover, develop and market Products, nor relieve Company of its obligations to pay Columbia any and all license fees,
royalties and other payments due under the Agreement, including but not limited to under Sections 4, 5 and 11 of the Agreement. 

c.    If applicable, all rights and licenses granted by Columbia to Company under this Agreement are subject to
(i) any limitations imposed by the terms of any government grant, government contract or government cooperative agreement that apply to the technology that is the subject of this Agreement, and (ii) applicable requirements of 35 U.S.C.
Sections 200 et seq., as amended, and implementing regulations and policies. The Company agrees that, to the extent required under 35 U.S.C. Section 204, any Product used, sold, distributed, rented or leased by Company,
Sublicensees, Designees, and their Affiliates in the United States will be manufactured substantially in the United States. In addition, the Company agrees that, to the extent required under 35 U.S.C. Section 202(c)(4), the United States
government is granted a non-exclusive, non-transferable, irrevocable, paid-up license to practice or have practiced for or on
behalf of the United States any Patent throughout the world. 
 d.    All rights not granted herein are reserved to
Columbia. Except as expressly provided under this Section 2, Columbia grants no right or license (expressly or by implication or estoppel) to Company or its Affiliates or Sublicensees under any tangible or intellectual property, materials,
patent, patent application, trademark, copyright, trade secret, know-how, technical information, data or other proprietary rights. 

  
 6 

 e.    During the term of this Agreement, Columbia and Company shall take
into consideration the principle of “Global Social Responsibility” in performing the various activities contemplated under this Agreement. “Global Social Responsibility” means facilitating the availability of (Licensed)
Products in “Developing Countries” (as defined below) at locally affordable prices, under reasonable circumstances and terms to improve access to such Products in Developing Countries. “Developing Countries” means those
countries listed by the World Bank as “Low-Income Economies,” as such list may change from time to time. Solely by way of example, the Parties may mutually agree to revise royalty rates,
adjust the fair market value, consider non-monetary consideration, and/or develop patent strategies in support of each party’s dedication to Global Social Responsibility. 

 

	3.	 Reservation of Rights for Research Purposes; Freedom of Publication. 

a.    Columbia reserves the right to practice the Patents solely for non-commercial
academic research and educational purposes in the Field and to permit other entities or individuals to practice and use such Patents solely for non-commercial academic research and educational purposes in the
Field. Columbia shall obtain from all such entities or individuals who are given permission to practice and use such Patents an agreement in writing to limit such use to non-commercial academic research and
educational purposes. For clarity, the parties hereby agree that (i) any clinical use and (ii) any research sponsored by a for-profit entity is a “commercial” purpose and not a “non-commercial” purpose for purposes of this Section 3a. 
 b.    The
Company acknowledges that Columbia is dedicated to the free scholarly exchange and to public dissemination of the results of its scholarly activities. Columbia and its faculty and employees may publish, disseminate or otherwise disclose any
information relating to its research activities, including Technical Information. 
  

	4.	 Fees, Royalties and Payment. 

a.    Importance of Technical Information and Materials. The Company has requested, and Columbia has agreed, to
grant certain rights to Technical Information and Materials. The Company requires these rights to develop and commercialize the technology licensed hereunder. Because of the importance of Technical Information and Materials, Company has agreed to
pay certain royalties to Columbia on Other Products, as specified below, even if it is not Covered By a Patent, to obtain rights to Technical Information and Materials. The Company has agreed to these payments because of the commercial value of
Technical Information and Materials, separate and distinct from the commercial value of the Patents. The Company acknowledges that it would not have entered into this Agreement without receiving the rights to the Technical Information and Materials
specified in Section 2. The Company further acknowledges that licenses to Technical Information, Materials, and each patent and application within the definition of Patents were separately available from a license to the Patents and that, for
convenience and because of the preference of the Company, the parties executed a combined license to the Patents, Technical Information, and Materials. 

b.    In consideration of the licenses granted under Section 2a of this Agreement, the Company shall pay to Columbia
as follows: 

  
 7 

 i.    License Fee: waived 

ii.    Annual Fee: The annual fee is waived for the first, second and third anniversaries of the Effective Date.
Company shall pay nonrefundable and non-recoverable annual license fees as follows: $[***] on the [***] anniversaries of the Effective Date; $[***] on the [***] anniversaries of the Effective Date; and $[***]
on the [***] anniversary of the Effective Date and each anniversary thereafter. Each annual fee payment will be credited against earned royalties accrued during the same calendar year in which the annual fee payment is due and payable. To the extent
the annual fee payment exceeds the earned royalties accrued during the same calendar year, this excess amount cannot be carried over to any other year, either to decrease the earned royalties due in that year or to decrease the annual fee due in
that year. 
 iii.    Royalties: 

A.    During the applicable Royalty Term, with respect to Net Sales of Products by Company and Sublicensees and any
Designees or Affiliates of the foregoing in the Territory, on a Product-by-Product and
country-by-country basis, a nonrefundable and non-recoverable royalty based on Net Sales of the applicable Product in a
particular country in a particular calendar year (“Annual Net Sales”) at the following rates: 

(1)    Patent Products: 
  

			
	 Annual Net Sales for a given Patent Product that is

Covered by a Patent in the country of sale
	  	 Royalty Rate

	Portion of Annual Net Sales during such calendar year that is less than or equal to [***]	  	[***]%
		
	Portion of Annual Net Sales during such calendar year that is greater than [***], but is less than or equal to [***]	  	[***]%
		
	Portion of Annual Net Sales during such calendar year that is greater than [***]	  	[***]%

 [***] 
 Other Products:

  

			
	 Annual Net Sales for a given Other
Product
	  	 Royalty Rate

	Portion of Annual Net Sales during such calendar year that is less than or equal to [***]	  	[***]%
		
	Portion of Annual Net Sales during such calendar year that is greater than [***], but is less than or equal to [***]	  	[***]%
		
	Portion of Annual Net Sales during such calendar year that is greater than [***]	  	[***]%

 [***] 

  
 8 

 (2)    In the event that it is required or necessary for Company, a
Sublicensee, or any Designee or Affiliate of the foregoing to pay royalties to a Third Party in order to avoid infringement of such Third Party’s patent rights that are necessary in order for Company to make, use or sell Products
(“Third Party Royalty”), Company may deduct [***] of such Third Party Royalty from the royalties due to Columbia under Section 4b(iii)(A)(1), provided that in no event will the royalties due to Columbia under
Section 4b(iii)(A)(1) be reduced by more than [***] of the amounts otherwise due to Columbia. Company will use its commercially reasonable efforts to require that all other Third Party licenses relating to the Product contain royalty stacking
relief provisions similar to those contained in this Section 4b(iii)(A)(3). 
 (3)    In the event of Third Party
Generic Competition with respect to a Product in a country in the Territory and the entry of such Third Party Generic Competition results in at least a [***] reduction of the Company’s Net Sales in such country in a particular [***],
which shall be measured against the Company’s Net Sales in the last complete [***] prior to entry of such Third Party Generic Competition in such country (“Percentage Reduction”), the royalties payable to Columbia for Net Sales
of Products under Section 4b(iii)(A) in the applicable country shall be reduced by the Percentage Reduction for each [***] royalty payment period that such Third Party Generic Competition has resulted in reducing the Company’s Net Sales
for that Product; provided that in no event will the royalties due to Columbia under Section 4b(iii)(A) be reduced by more than [***] of the amounts otherwise due to Columbia for a given [***]. In the event that Company’s Net Sales for
such Product in such country returns to the level of Company’s Net Sales of such Product in the last complete [***] prior to entry of such Third Party Generic Competition in such country, Company shall not be entitled to reduce royalties on Net
Sales of Products by the Percentage Reduction under this Section 4b(iii)(A) for such [***]; provided, for clarity, Company shall be entitled to take such reduction in subsequent [***] to the extent such Generic Competition results in at least a
[***] reduction of the Company’s Net Sales in such country, as per the above. 
 iv.    Equity: On the
Effective Date, Columbia will purchase and the Company will issue to Columbia shares of the Company’s Common Stock pursuant to the Stock Purchase Agreement in the form attached hereto as Exhibit B (the “Purchase
Agreement”). Columbia will then have those rights and privileges as a stockholder of the Company as are set forth in the Purchase Agreement. 

c.    In consideration of Company’s right to sublicense granted under Section 2b of this Agreement, Company
shall pay to Columbia the following nonrefundable, non-recoverable and non-creditable amounts: 

i.    Reserved. 

ii.    Non-Royalty Sublicensing Income: The following percentage of any and
all other consideration (including any premium above fair market value for debt and/or equity securities or instruments, or the market value of an arm’s-length transaction of any cross-licensing rights
granted by Sublicensee to Company), including without limitation, any upfront, milestone or lump sum payments (including but are not limited to payments for the achievement of patent, pre-clinical, clinical,
regulatory, sales or any other milestone), and/or fair market value 

  
 9 

 
of any non-cash consideration, received by Company from Sublicensees, their Designees or their Affiliates as full or partial consideration for the grant of
any sublicense (or any option or any right to negotiate for sublicense) by Company under Section 2b of this Agreement (“Non-Royalty Sublicensing Income” or “NRSI”): 

 

			
	 Event
	  	 Percentage (%) of Non-Royalty Sublicensing Income

	[***]	  	[***]% of NRSI
		
	[***]	  	[***]% of NRSI
		
	[***]	  	[***]% of NRSI

 NRSI shall not include any of the following: (a) royalties on Net Sales of Products; (b) payments by Sublicensees,
Designees or any Affiliates of the foregoing for payment or reimbursement of patent prosecution, defense, enforcement or maintenance expenses in respect of the Patents; (c) the fair market value of payments received by Company from a
Sublicensee for any debt and/or equity securities or instruments issued by Company, or payments for an acquisition of all or substantially all of its assets that include the assignment of this Agreement; and (d) funds received from a
Sublicensee, Designee or any Affiliate of the foregoing for bona fide research and development of Products (including payments for FTEs), which research and development is conducted after the actual date of execution of the Sublicense. To the extent
that patent rights, other intellectual property rights or other rights or obligations other than Patents, Technical Information or Materials are licensed, sublicensed or granted by Company, that portion of the consideration received by Company shall
be equitably apportioned between the Patents, Technical Information and Materials and those other rights and obligations, and such apportionment shall be reasonable and in accordance with customary standards in the industry. In the event that
Columbia disagrees, in good faith, with Company’s apportionment, the Parties will meet and discuss in good faith and if the Parties are unable to reach agreement on the apportionment, the issue will be submitted to a neutral third party expert
acceptable to both Parties to determine an equitable apportionment. 
 d.    Development Milestone Payments. 

i.    If the Company, Sublicensees, or the Designees or Affiliates of any of foregoing (collectively
“Developer”) develops a Patent Product for potential commercial sale in the Territory, Company shall pay Columbia the following nonrefundable, non-recoverable and non-creditable milestone payments as follows, with respect to each and every Patent Product that meets each milestone set forth below: 

A.    $[***] on [***]; 

B.    $[***] [***]; 

C.    $[***] upon [***]; 

D.    $[***] upon [***]; 

E.    $[***] upon [***]; 

  
 10 

 F.    $[***] upon [***]; 

G.    $[***] upon [***]; and 

H.    $[***] upon [***]. 

ii.    If a Developer develops an Other Product for potential commercial sale in the Territory, Company shall pay Columbia
one-half of the milestone payments set forth in Section 4d(i)(A) through Section 4d(i)(H) with respect to each and every such Other Product, which milestone payment shall be nonrefundable, non-recoverable and non-creditable. 

iii.    A milestone payment equal to one-half of the milestone payments set forth
in Section 4d(i)(C) through Section 4d(i)(H) shall apply to each subsequent indication for an already-approved Product. For clarity, an already approved Product as used in this provision shall mean a Product with the same active
pharmaceutical ingredient (“API”) that has already obtained US FDA approval or regulatory approval in the United Kingdom, Europe, Japan, Canada, China or Australia for another indication. 

iv.    In the event one or more of the above milestones are achieved in conjunction with, or solely by, a Sublicensee,
Columbia will receive the greater of (A) the milestone payment indicated in Section 4d(i) or (B) the percentage of NRSI pursuant to Section 4c(ii). In no event will Company be obligated to pay Columbia under Section 4d(i)
and Section 4c(ii) for the achievement of the same event. 
 e.    Duration of Product Royalties. Royalties
on each particular Product are payable on a country-by-country and Product-by-Product
basis until the later of (i) the date of expiration of the last to expire Valid Claim Covering such Product, (ii) twenty (20) years after the first bona fide commercial sale of such particular Product in such country, or
(iii) expiration of any market exclusivity period granted by a regulatory agency in such country; provided that subsection (ii) is applicable only with respect to Other Products and not Patent Products (the “Royalty
Term”). 
 f.    Highest Royalty Due. If a Product is both a Patent Product and an Other Product,
Company shall pay Columbia the Patent Product royalty rate on the Product during the Royalty Term when such Product is a Patent Product and will pay the Other Product royalty rate on the Product for the remainder of any Royalty Term to the extent
such Product is an Other Product. The Company will not be obligated to pay Columbia more than one royalty payment on the same Product sale under Section 4. By way of example, but not by way of limitation, if, as of the date of first commercial
sale of a given Product in a given country, such Product is Covered by a Valid Claim of a Patent in such country of sale (so is a Patent Product), and such Product also incorporates in part Technical Information (so is an Other Product), Company is
obligated to pay the royalty specified in Section 4b(iii)(A)(1). If, after some period of time (for example, five years) of paying the royalties specified in Section 4b(iii)(A)(1) on the Product, the Product ceases to be a Patent Product
in a given country, Company shall continue to pay royalties on the Product under Section 4b(iii)(A)(2) for the remainder of the Royalty Term in such country. 

g.    No Non-Monetary Consideration. In the event that Company or any of
its Affiliates receive non-cash consideration for (i) the sale of any Product other than as will be accurately reflected in Net Sales, or (ii) from a Sublicensee, Designee or any Affiliate of the

  
 11 

 
foregoing, all payments due hereunder resulting therefrom shall be calculated based on Net Sales of such Product received by Company in the prior [***] or if not available, the fair market value
of such consideration as reasonably estimated by the Parties. Furthermore, Company shall not enter into any transaction with any Affiliate that would circumvent its monetary or other obligations under this Agreement. 

h.    Rate Adjustment on Challenge; Payment of Costs and Expenses. 

i.    If Company (or any entity or person acting at Company’s request and direction) initiates any proceeding or
otherwise asserts any claim challenging the validity or enforceability of any Patent in any court, administrative agency or other forum (“Challenge”), all royalty rates, minimum royalties, and other payment rates in
Sections 4b(iii) and 4c with respect to the Patent subject to such Challenge shall be automatically multiplied by [***] on and after the date of such Challenge for the remaining term of this Agreement. 

ii.    Company shall pay all reasonable costs and expenses incurred by Columbia (including actual legal fees) in
connection with defending a Challenge. Columbia may bill Company [***] concerning such costs and expenses, and Company shall make payment no later than [***] after receiving an invoice from Columbia. 

iii.    If at least one Valid Claim of a Patent that is subject to a Challenge survives the Challenge by not being found
invalid or unenforceable, regardless of whether the Valid Claim is amended as part of the Challenge, all royalty rates, minimum royalties, and other payment rates in Sections 4b(iii) and 4c with respect to the Patent subject to such challenge
shall be automatically [***] on and after the date of such finding for the remaining term of this Agreement. If no Valid Claim of a Patent that is subject to a Challenge survives the Challenge by being found invalid or unenforceable, regardless of
whether the Valid Claim is amended as part of the Challenge, all royalty rates and other payment rates set forth in Sections 4b(iii) and 4c shall revert to those originally set forth above for the remaining term of this Agreement. 

A Sublicensee will not be deemed to be acting at Company’s request and direction if such Sublicensee initiates a Challenge and Company terminates the
sublicense of rights granted by Company to such Sublicensee within [***] days of Company becoming aware of the initiation of such Challenge. Such termination shall be deemed to have rendered the Challenge void ab initio and the results described in
the foregoing clauses (i) through (iii) (inclusive) shall not be given effect in connection with such Challenge. 
 The Company acknowledges that this
Section 4h reasonably reflect the value derived from the Agreement by the Company in the event of a Challenge. In addition, the Company acknowledges that any payments made under this Section 4h are nonrefundable and non-recoverable for any reason whatsoever. 
 iv.    Royalties for Sales of
Products Below Fair Market Value. If Company, Sublicensees, Designees or their Affiliates sell Product to a Third Party to whom it also sells other products not covered under this Agreement, and the Net Sales of such Product is below the fair
market value of such Product (as determined by the valuation of an independent Third Party mutually acceptable to Company and Columbia) due to the intent of the Company, 

  
 12 

 
Sublicensees, Designees or their Affiliates of increasing market share for such other products sold by Company, Sublicensees, Designees or their Affiliates to such Third Party, then the royalties
due to Columbia under Section 4b(iii) shall be based on the fair market value of the Product. For the purposes of this provision, the fair market value of the Product shall be determined based on the sales of the same Product in the last [***]
in the same country to similarly sized Third Parties. 
 5.    Reports and Payments. 

a.    No later than [***] days after the first business day of each [***] of each License Year of this Agreement commencing
with the calendar year during which the first bona fide commercial sale of a Product to a Third Party occurs, Company shall submit to Columbia a written report with respect to the preceding [***] (the “Payment Report”) that includes
the following: 
 i.    Gross and Net Sales of Products by Company, Sublicensees, Designees and their Affiliates during
such [***], together with detailed information sufficient to permit Columbia to verify the accuracy of reported Net Sales, including Product names, country where manufactured, country where sold, actual selling price, units sold, an identification
of all Patent claims that any Patent Product is Covered By, and an identification of Materials and Technical Information used or incorporated in the discovery, development, manufacture, use, sale, offering for sale, importation, exportation,
distribution, rental or lease of any Other Product; 
 ii.    Amounts accruing to, and amounts received by, Company from
its Sublicensees during such [***] together with the respective payment reports received by Company from any Sublicensees; 

iii.    A calculation under Section 4 of the amounts due to Columbia, making reference to the applicable
subsection thereof; and 
 iv.    The exact date of the first commercial sale of a Product in the first Payment
Report for such Product. 
 v.    A copy of each report any Sublicensee has sent to Company that is pertinent to any
royalties or other sums owing to Company for the preceding [***]; provided, however, that any portions of such reports that are not necessary for Columbia to assess the amounts payable to it hereunder may be subject to reasonable redaction as
necessary for Kures (or its Sublicensees) to comply with obligations of confidentiality. 
 Simultaneously with the submission of each Payment Report,
Company shall make payments to Columbia of the amounts due for the [***] covered by the Payment Report. Company shall pay by check payable to The Trustees of Columbia University in the City of New York and sent to the following address: 

The Trustees of Columbia University in the City of New York 

Columbia Technology Ventures 

P.O. Box 1394 
 New York, NY
10008-1394 

  
 13 

 or to such other address as Columbia may specify by notice hereunder, or if requested by Columbia, by wire
transfer of immediately available funds by Company to: 
 [***] 

or to such other bank and account identified by notice to Company by Columbia. Company shall pay for all bank charges for the wire transfer of funds for
payments to Columbia and shall not deduct bank charges from the total amount due to Columbia. Company shall send the [***]royalty statement whether or not royalty payments are due. 

b.    No later than [***] days after the date of termination or expiration of this Agreement, Company shall pay Columbia
any and all amounts that are due under this Agreement as of the date of such termination or expiration, together with a Payment Report for such payment in accordance with this Section 5, except that such Payment Report will cover the period
from the end of the last [***] before termination or expiration to the date of termination or expiration. Nothing in the foregoing is deemed to satisfy any of Company’s other obligations under this Agreement upon termination or expiration. 

c.    Annual fee payments are payable in accordance with Section 4b(ii). 

d.    With respect to revenues obtained by Company in foreign countries, Company shall make royalty payments to Columbia
in the United States in United States Dollars. For royalty payments for transactions outside the United States, Company shall first determine the royalty in the currency of the country in which it is earned, and then converted that currency to
United States dollars using the buying rates of exchange quoted by The Wall Street Journal (or its successor) in New York, New York for the last business day of the [***] in which the royalties were earned. Company shall pay any and all loss of
exchange value, taxes, or other expenses incurred in the transfer or conversion of foreign currency into U.S. dollars, and any income, remittance, or other taxes on such royalties required to be withheld at the source, and shall not decrease the
amount of royalties due to Columbia hereunder. Royalty statements will show sales both in the local currency and US dollars, with the applicable exchange rate used clearly stated. 

e.    Company shall maintain at its principal office books of account sufficient to reasonably determine the
Company’s compliance with its obligations hereunder. Upon reasonable notice, but not more than [***] per calendar year, Columbia may have an independent certified public accountant or auditor (each as to whom Company has no reasonable
objection) inspect such books and records for purposes of verifying the accuracy of the amounts paid under this Agreement. The review may cover a period of not more than [***] years before the first day of the [***] in which the review is requested.
If such a review shows the Company has underpaid by [***] or more concerning any [***] then the Company shall pay, no later than [***] days after a demand by Columbia, the costs and expenses of such review (including the fees charged by
Columbia’s accountant and in house attorney involved in the review), in addition to the amount of any underpayment and any interest thereon. The Company agrees to cooperate fully with Columbia’s accountant or auditor and in house attorney
in connection with any such review. During the review, the Company shall provide Columbia’s accountant or auditor and attorney with all information reasonably requested to allow the accountant or auditor and
in-

  
 14 

 
house attorney to audit and test for completeness, including without limitation, information relating to sales, inventory, manufacturing, purchasing, transfer records, customer lists, invoices,
purchase orders, sales orders, shipping documentation, Sublicensee royalty reports, cost information, pricing policies, and agreements with Sublicensees, the Designees, the Affiliates of the Company and the customers). 

f.    Notwithstanding anything to the contrary in this Agreement (including Section 15b), and without limiting any of
Columbia’s rights and remedies hereunder, any payment required hereunder that is made late (including unpaid portions of amounts due shall bear interest, for the period for which such payment was not paid when due, at the U.S. prime rate plus
[***] as published by the Wall Street Journal on the last day of the applicable billing period. Any interest charged or paid in excess of the maximum rate permitted by New York State Law shall be deemed the result of a mistake and Columbia shall
credit or refund (at the Company’s option) to the Company the interest paid in excess of the maximum rate. All information provided under this Section 5(f) shall be considered Company’s Confidential Information hereunder, whether or
not marked or otherwise designated as such. 
 g.    Company shall reimburse Columbia for any reasonable costs and
expenses incurred in connection with collecting on any arrears of Company with respect to its payment and reimbursement obligations under this Agreement (such as Section 11b of this Agreement), including the costs of engaging any collection
agency for such purpose. 
 h.    Company shall submit to Columbia annual
non-binding forecasts on the first business day following January 1 for annual sales of Products by Company, Sublicensees, Designees and their Affiliates to Columbia for its internal budget purposes. 

6.    Diligence. 

a.    Company (itself or through its Affiliates or Sublicensees) shall use commercially reasonable efforts to research,
discover, develop and market at least one (1) Tianeptine Product and at least one (1) Mitragynine Product for commercial sale and distribution in the Territory. Company shall be deemed to meet such “commercially reasonable
efforts” in the event it achieves all of the due diligence milestones set forth in this Article 6. Company shall achieve the following due diligence milestones (“Milestones”) for at least one Tianeptine Product and at
least one Mitragynine Product by the dates (“Achievement Dates”) as set forth below: 
 i.    Due
Diligence Milestones for the Tianeptine Products: 
  

			
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

  
 15 

 ii.    Due Diligence Milestones for the Mitragynine Products:

  

			
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]

 b.    In the event that Company is unable to achieve the diligence milestones in
Section 6a(i), Columbia may exercise its right in accordance with Section 15 solely to terminate the license under the Tianeptine Patents and Tianeptine Technical Information granted to Company in Section 2, but not under the
Mitragynine Patents or Mitragynine Technical Information. In the event that Company is unable to achieve the diligence milestones in Section 6a(ii), Columbia may exercise its right in accordance with Section 15 solely to terminate the
license under Mitragynine Patents and Mitragynine Technical Information granted to Company in Section 2, but not under the Tianeptine Patents or Tianeptine Technical Information. Notwithstanding any other provisions of this Agreement, if
Company does not achieve any of Company’s diligence obligations under this Section, Columbia may terminate all of the licenses granted under Section 2 in accordance with Section 16 of this Agreement, or Columbia may convert any or all
of such exclusive licenses to non-exclusive licenses with no right to sublicense and no right to initiate legal proceedings under Section 11; provided that Company may first request a reasonable extension
to the performance period of the above milestones and Columbia shall reasonably grant such extension if Company has exercised commercially reasonable efforts to achieve the target completion date and has a plan to achieve it within the extension
period. 
 c.    No less often than every twelve (12) months after the Effective Date of this Agreement until the
date of the first bona fide commercial sale of a Product, Company shall report in writing to Columbia on progress made toward the diligence objectives set forth above, using Exhibit D to this Agreement or an equivalent to Exhibit D to make
the report. 
 7.    Confidentiality. 

a.    Except to the extent required to discover, develop, manufacture, have manufactured, use, sell, have sold, offer for
sale, import, export, distribute, commercialize, rent or lease Products in the Field, Company shall treat as confidential the Patents, Materials and Technical Information disclosed hereunder, and shall not disclose or distribute them to any Third
Party without Columbia’s written permission. 
 b.    Except to the extent required to verify Company’s
compliance with the terms hereof or as required by Columbia policies and statutes, Columbia will, and will require its auditors, attorneys and accountants to, treat as confidential all copies of sublicense or other agreements, Payment Reports,
progress reports, information contained in Company’s books of account and records and other information under Section 5e, in each case provided or made available hereunder, and Columbia will not, and will require its auditors, attorneys
and accountants not to, disclose or distribute the same to any Third Party without Company’s written permission. 

  
 16 

 c.    The obligations of confidentiality under this Section 7 do
not apply to any Patents, Materials or Technical Information or other items or information that the receiving party can demonstrate: 

i.    was known to the receiving party before receipt thereof from the disclosing party; 

ii.    was or became a matter of public information or publicly available through no act or failure to act on the part of
the disclosing party; 
 iii.    was acquired by the receiving party from a third party entitled to disclose it to the
receiving party; or 
 iv.    the receiving party discovers or developed independently without reference to or use of
such Patents, Materials or Technical Information or other items or information, as evidenced by contemporaneous written records. 

d.    Each party shall hold in confidence and shall not disclose to any other person or entity (other than their
directors, employees, legal counsel and accountants who, except in the case of legal counsel, are bound in writing by confidentiality obligations no less restrictive than those set forth herein) the terms and conditions of this Agreement.
Notwithstanding the foregoing, Company may disclose the unredacted terms and conditions of this Agreement to comply with disclosure requirements of all applicable laws relating to its business, including United States and state securities laws.
Further, Company may disclose the unredacted terms and conditions of this Agreement to bona fide Third Parties in connection with a proposed permitted assignment of this Agreement, Sublicensees, Designees, investment bankers, investors and lenders,
and their directors, employees, legal counsel and accountants; provided such bona fide Third Parties, Sublicensee or Designee must be bound prior to disclosure by confidentiality obligations no less restrictive than those set forth
herein, and such investment bankers, investors and lenders must be bound prior to disclosure by commercially reasonable obligations of confidentiality. 

e.    If either Party (the “Disclosing Party”) is required to make a disclosure of the other Party’s
(the “Objecting Party”) confidential information pursuant to an order of a court of competent jurisdiction or other governmental agency or authority, the Disclosing Party shall first give the Objecting Party such notice and
opportunity as is reasonably practical under the circumstances to quash the order or to obtain a protective order requiring that the confidential information be held in confidence or used only for the purpose for which the order was issued; and
provided further that if such order is not quashed or a protective order is not obtained, the confidential information disclosed shall be limited to the information that is legally required to be disclosed. The Disclosing Party shall so advise the
Objecting Party if and when it is required to make such disclosure so that the Objecting Party may seek an injunction or other order prohibiting such disclosure of confidential information. 

  
 17 

 f.    Defend Trade Secrets Act. Under 18 U.S.C. §1833(b), “An
individual shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that (A) is made (i) in confidence to a Federal, State, or local government official, either
directly or indirectly, or to an attorney; and (ii) solely for the purpose of reporting or investigating a suspected violation of law; or (B) is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing
is made under seal.” Nothing in this Agreement or any Columbia policy is intended to conflict with this statutory protection, and no Columbia trustee, director, officer, or member of management has the authority to impose any practice to the
contrary. 
 8.    Disclaimer of Warranty; Limitations of Liability. 

a.    Columbia hereby represents and warrants to Company that all inventors listed on the Patents as of the Effective Date
have assigned all right, title, and interest to Columbia or Memorial Sloan Kettering Cancer Center (“MSKCC”) and Columbia and MSKCC have entered into an inter-institutional agreement in which MSKCC has granted Columbia the power and
authority to grant the licenses provided for herein to Company on behalf of MSKCC, and that to the best of its knowledge as of the Effective Date, its office of Columbia Technology Ventures has not executed any agreement and will not knowingly
execute into any agreement during the term of this Agreement that would materially conflict with the rights granted to Company herein. 

b.    Columbia is licensing the patents, materials, technical information, and the subject of any other license
hereunder, on an “as is” basis. Except as expressly provided in Section 8a, neither Company nor Columbia makes any warranties either express or implied of any kind, and hereby expressly disclaims any
warranties, representations or guarantees of any kind as to the Patents, Materials, Technical Information, Products and/or anything discovered, developed, manufactured, used, sold, offered for sale, imported, exported, distributed, rented, leased or
otherwise disposed of under any license granted hereunder, including but not limited to the following: any warranties of merchantability, title, fitness, adequacy or suitability for a particular purpose, use or result; any warranties as to the
validity of any patent; and any warranties of freedom from infringement of any domestic or foreign patents, copyrights, trade secrets or other proprietary rights of any party. 

c.    In no event will Columbia, or its trustees, officers, faculty members, students, employees and agents, have any
liability to Company, Sublicensees, Designees, or Affiliates of the foregoing, or any Third Party arising out of the use, operation or application of the Patents, Technical Information, Materials, Products, or anything discovered, developed,
manufactured, used, sold, offered for sale, imported, exported, distributed, rented, leased or otherwise disposed of under any license granted hereunder by Company, Sublicensees, Designees or Affiliates of the foregoing, or any Third Party for any
reason, including but not limited to, the unmerchantability, inadequacy or unsuitability of the Patents, Materials, Technical Information, Products and/or anything discovered, developed, manufactured, used, sold, offered for sale, imported,
exported, distributed, rented, leased or otherwise disposed of under any license granted hereunder for any particular purpose or to produce any particular result, or for any latent defects therein. 

  
 18 

 d.    In no event will, on the one hand, Company, Sublicensees,
Designees or Affiliates of the foregoing, or any of their respective officers, directors, employees or agents, or, on the other hand, Columbia, or its trustees, officers, faculty members, students, employees and agents, be liable to Columbia in the
first instance or, in the second instance, the Company, Sublicensees, Designees or Affiliates of the foregoing, or any Third Party, for any consequential, incidental, special or indirect damages (including, but not limited to, from any destruction
to property or from any loss of use, revenue, profit, time or goodwill) based on activity arising out of or related to this Agreement, whether pursuant to a claim for breach of contract or any other claim of any type. 

e.    In no event will Columbia’s liability to Company exceed the payments made to Columbia by Company under this
Agreement. 
 f.    The parties hereto acknowledge that the limitations and exclusions of liability and disclaimers of
warranty in this Agreement form an essential basis of the bargain between the parties. 
 9.    Prohibition Against Use of Name.

 Neither Party shall not use the name, insignia, or symbols of the other Party, its faculties or departments, or any variation or
combination thereof, or, in the case of Company, the name of any trustee, faculty member, any other employee, or student of Columbia, for any purpose whatsoever without the other Party’s prior written consent. The foregoing notwithstanding,
without the consent of Columbia, Company may state, in a factual manner only, that it is licensed by Columbia under the Patents, Materials and Technical Information and identify the inventors of the Patents, their affiliation with Columbia, and
their relationship to the Company, and further, Company may comply with disclosure requirements of all applicable laws relating to its business, including United States and state security laws. In no event will Company, its Affiliates or
Sublicensees use Columbia’s name in any manner that would suggest or imply that Columbia endorses any product or services provided by the Company, its Affiliates or Sublicensees. 

10.    Compliance with Governmental Obligations. 

a.    Notwithstanding any provision in this Agreement, Columbia disclaims any obligation or liability arising under this
Agreement if Company or its Affiliates is charged in a governmental action for not complying with governmental regulations in the course of taking steps to bring any Product to a point of practical application. 

b.    Company and its Affiliates shall comply upon reasonable notice from Columbia with all governmental requests directed
to either Columbia or Company or its Affiliates and provide all information and assistance necessary to comply with the governmental requests. 

c.    Company and its Affiliates shall make all reasonable efforts to ensure that research, development, manufacturing and
marketing of Products under this Agreement complies with all applicable government regulations in force and effect including, but not limited to, Federal, state, and municipal legislation. 

  
 19 

 11.    Patent Prosecution and Maintenance; Litigation. 

a.    Subject to Section 11b, Columbia, by counsel it selects and who is reasonably acceptable to Company, in
consultation with Company and any counsel appointed by the Company, shall prepare, file, prosecute and maintain all Patents in Columbia’s name and in countries designated by the Company. Columbia shall instruct its patent counsel (i) to
copy Company on all correspondence related to Patents (including copies of each patent application, office action, response to office action, request for terminal disclaimer, and request for reissue or reexamination of any patent or patent
application) and (ii) as requested by Company, to provide an update as to the current status of all Patents. The parties intend that consultation between the parties relating to the Patents under this Section 11 will be in accordance with
a common interest in the validity, enforceability and scope of the Patents. In furtherance thereof, Columbia shall promptly provide Company with a copy of any proposed patent applications within the Patents, and any other significant filing related
to such Patents, sufficiently in advance of any filling thereof to allow Company to comment thereon, which comments Columbia will consider in good faith. Each party shall treat such consultation, along with any information disclosed by each party in
connection therewith (including any information concerning patent expenses), on a confidential basis, and shall not disclose such consultation or information to any Third Party without the other party’s prior written consent. Except as provided
for in Section 11c, Columbia will not allow any rights to Patents to go abandoned without giving Company at least [***] advance written notice so that Company can provide comments to Columbia, which Columbia shall consider in good faith. If
Company seeks to challenge the validity, enforceability or scope of any Patent, Columbia’s consultation obligation under this Section 11a shall automatically terminate; any such termination will not affect Company’s confidentiality
and nondisclosure obligations with respect to consultation or disclosure of information before such termination, and will not affect any other provisions of this Agreement (including Company’s reimbursement obligation under Section 11b).

 b.    [***] 

i.    [***] 

ii.    [***] 

c.    In the event that Columbia or Company learns of possible or actual infringing activity by a Third Party of any
patent in the Patent Rights, the knowledgeable party will promptly provide the other party with notice of such infringement, which shall include any evidence of such infringement available to it. Subject to Sections 11d and 11f, as between the
parties, Columbia shall have the first right, but not the obligation, to initiate, control, defend and/or settle any proceedings involving the validity, enforceability or infringement of any Patents when in its judgment such action may be necessary,
proper, and justified. 
 d.    Upon written notice to Columbia, Company may request that Columbia take steps to stop a
third party who is selling a product that does or will compete with a Product sold or being developed by Company or any of its Affiliates (but not a Sublicensee, or Sublicensee Affiliate) (“Third-Party Infringer”) from infringing an
issued patent falling within the definition of Patents by providing Columbia with written evidence demonstrating a reasonable 

  
 20 

 
basis for infringement of specific claims of such Patent. Company may initiate any such legal proceedings against any such Third-Party Infringer in its own name and [***], unless Columbia, not
later than [***] days after receipt of such notice, either (i) causes such infringement to cease or (ii) initiates legal proceedings against the Third-Party Infringer. Company shall provide all assistance reasonably requested by Columbia
and shall not make any admission or assert any position in any legal or administrative proceeding that is inconsistent with or adverse to any position asserted by Columbia in any proceedings against the Third-Party Infringer, without Columbia’s
prior written consent. [***]. Any proposed disposition or settlement of a legal proceeding filed by Company to enforce any issued patent falling within the definition of Patents against any Third-Party Infringer is subject to Columbia’s prior
written approval, and Columbia shall not unreasonably withhold or delay its approval. Company’s rights under this Section 11d apply only to claims of Patents that are exclusively licensed to Company under this Agreement and only in the
Field and Territory that are exclusively licensed to Company under this Agreement. 
 e.    Any recovery, whether by way
of settlement or judgment received pursuant to a legal proceeding initiated in accordance with Section 11d, shall first be used to reimburse the party initiating such legal proceeding for its actual fees, costs and expenses incurred in
connection with such proceeding, and next to the other party for its actual fees, costs and expenses incurred in connection with such proceeding. The balance of such recovery shall be divided as follows: 

i.    [***]; and 

ii.    [***]. 

f.    If a party initiates or defends a legal proceeding concerning any Patent under this Section 11, the other party
shall cooperate fully with and supply all assistance reasonably requested by the party initiating such proceeding, including without limitation, joining the proceeding as a party if requested, at the requesting party’s expense. The party that
institutes any legal proceeding concerning any Patent under this Section 11 shall have sole control of that proceeding. 

12.    Indemnity and Insurance. 

a.    Company shall indemnify, defend, and hold harmless Columbia, its trustees, officers, faculty, employees, students and
agents, from and against any and all Third Party actions, suits, claims, demands, prosecutions, liabilities, costs, expenses, damages, deficiencies, losses or obligations (including reasonable legal fees) based on, arising out of, or relating to
this Agreement, including, without limitation, (i) the discovery, development, manufacture, packaging, use, sale, offering for sale, importation, exportation, distribution, rental or lease of Products, even if altered for use for a purpose not
intended, (ii) the use of Patents, Materials or Technical Information by Company, Sublicensees, Designees, or their Affiliates or customers, (iii) any representation made or warranty given by Company, Sublicensees, Designees, or their
Affiliates with respect to Products, Patents, Materials or Technical Information, (iv) any infringement claims relating to Products, Patents, Materials or Technical Information, and (v) any asserted violation of the Export Laws (as defined
in Section 14) by Company, Sublicensees, 

  
 21 

 
Designees, or their Affiliates; in each case, except to the extent it is determined to arise from the gross negligence or intentional misconduct of any person or entity seeking indemnification
hereunder Each indemnified person or entity shall promptly notify Company thereof and afford Company full control over the defense and settlement thereof, and reasonably cooperate with Company in such defense. Company shall reimburse Columbia for
the actual fees, costs, and expenses (including legal fees) that it may incur in enforcing this provision. 

b.    Commencing at least [***] prior to the first Product being offered for sale, Company shall obtain and maintain
during the remaining term of this Agreement, Commercial General Liability insurance (including product liability and contractual liability coverage for Company’s indemnity obligations under Section 12a) with reputable and financially
secure insurance carriers reasonably acceptable to Columbia to cover the activities of Company, Sublicensees, Designees, and their Affiliates, for minimum limits of $[***] combined single limit for bodily injury and property damage per occurrence
and in the aggregate. Such insurance shall include Columbia, its trustees, faculty, officers, employees and agents as additional insureds. Company shall furnish a certificate of insurance evidencing such coverage, with [***] days’ written
notice to Columbia of cancellation or material change in coverage. The minimum amounts of insurance coverage required herein shall not be construed as creating any limitation on the Company’s indemnity obligation under Section 12a of this
Agreement. 
 c.    Company’s insurance shall be primary coverage; any insurance Columbia may purchase shall be
excess and noncontributory. The Company’s insurance shall be written to cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement. 

d.    Company shall comply with all statutory workers’ compensation and employers’ liability requirements
covering its employees with respect to activities performed under this Agreement. 
 13.    Marking. 

Before the issuance of patents falling within the definition of Patents, Company shall mark all Patent Products made, sold, offered for sale,
imported, or otherwise disposed of by Company under the Patent license granted in this Agreement with the words “Patent Pending,” and following the issuance of one or more patents, with the numbers of such patents, in each case to
the extent commercially feasible, consistent with prevailing business practices and as required by applicable law. The Company shall cause its Affiliates, and its Sublicensees and Designees and their Affiliates, to comply with the marking
requirements of this Section 13. 
 14.    Export Control Laws. 

a.    Company agrees to comply with applicable U.S. export laws and regulations pertaining to the export of technical data,
services and commodities, including the International Traffic in Arms Regulations (22 C.F.R. § 120 et seq.), the Export Administration Regulations (15 C.F.R. § 730 et seq.), the regulations administered by the Treasury
Department’s Office of Foreign Assets Control (31 C.F.R. § 500, et seq.), and the Anti-Boycott Regulations (15 C.F.R. § 760) (individually and collectively, “Export Laws”). The parties shall cooperate with
each other to facilitate compliance with these laws and regulations. 

  
 22 

 b.    The Company understands that sharing controlled technical data
with non-U.S. persons is an export to that person’s country of citizenship that is subject to U.S. export laws and regulations, even if the transfer occurs in the United States. The Company shall obtain
any necessary U.S. government license or other authorization required under the U.S. export control laws and regulations for the export or re-export of any commodity, service or technical data covered by this
Agreement, including technical data acquired from Columbia under this Agreement and products created as a result of that data. 

15.    Breach and Cure. 

a.    Company shall be deemed to be in material breach of this Agreement for: (i) failure to pay fully and promptly
amounts due under Section 4 and payable under Sections 5 and 11; (ii) failure of Company to issue Columbia shares of the Company’s Common Stock in accordance with Section 4b(iv) and the Purchase Agreement; (iii) failure of
Company to meet any of its obligations under Section 6 of this Agreement; (iv) failure to use its reasonable efforts to comply with governmental requests directed to Columbia or Company under Section 10b; (v) [***]; (vi) failure to
obtain and maintain insurance in the amount and of the type provided for in Section 12; and (vii) failure to comply with the Export Laws under Section 14. 

b.    Either party shall have the right to cure its material breach. The right to cure shall be effected within a
reasonable period of time but in no event later than [***] days after notice of any breach of payment obligations given by the non-breaching party, or [***] days after notice of any other breach given by the non-breaching party. 
 16.    Term of Agreement. 

a.    This Agreement is effective as of the Effective Date and continues in full effect until its expiration or termination
in accordance with this Section 16. In addition, upon any termination of this Agreement under Section 16c, Company agrees upon request by Columbia within [***] days of termination to enter into good faith negotiations with Columbia or
Columbia’s future licensee(s) for the purpose of granting licensing rights (subject to Company’s pre-existing licenses) to (i) all know-how, technical
information and data developed by Company (“Company Technical Information”) during the term of this Agreement, and before its termination, to the extent such Company Technical Information is necessary to exploit the Company Patents;
and (ii) all Company filed patent applications or Company obtained patents, related to any addition, development, modification and/or improvement of Products (“Company Patents”). 

b.    Unless terminated earlier under any provision of this Agreement, the term of the licenses granted hereunder extend,
on a country-by-country and Product-by-Product basis, until the expiration of the Royalty
Term for such Product in such country. Following the end of the Royalty Term for any Product in a country by expiration (but not termination), the license granted to Company in Section 2 with respect to such Product in such country will become
perpetual, irrevocable, fully paid-up and royalty-free. 

  
 23 

 c.    Company may terminate this Agreement in its entirety, with respect
to Tianeptine Products only, or with respect to Mitragynine Products only upon ninety (90) days’ prior written notice to Columbia; provided that Company has reimbursed in full to Columbia the Past Patent Expenses with respect to the
Mitragynine Products or Tianeptine Products, as applicable. 
 d.    This Agreement may be terminated by Columbia or, at
Columbia’s option, Columbia has the right to convert any or all of such exclusive licenses granted under this Agreement to non-exclusive licenses, with no right to sublicense, and no right by Company to
initiate legal proceedings under Section 11: (i) upon at least [***] days after written notice to Company if Columbia elects to terminate in accordance with Section 6b and Company fails to cure in accordance with Section 15b;
(ii) upon written notice to Company for Company’s material breach of the Agreement and Company’s failure to cure such material breach in accordance with Section 15b; (iii) upon termination of the Purchase Agreement by
Columbia for Company’s failure to cure a material breach; (iv) if Company becomes insolvent or is generally not paying its debts as such debts become due; and(v) if Company ceases to conduct business as a going concern. Termination under
(ii) – (v) is effective upon the date the notice is sent under Section 17. 
 e.    Upon any termination of
this Agreement under Section 16d, all sublicenses granted by the Company under this Agreement shall be assigned to Columbia, upon request and at Company’s discretion, provided that Columbia’s obligations under such sublicense shall be
consistent with and not exceed Columbia’s obligations to Company under this Agreement and that the Sublicensee agrees in a writing sent to Columbia to assume all obligations of this Agreement for the benefit of Columbia to the extent of the
applicable sublicense, including the obligations to make all payments due under this Agreement, including but not limited to those specified in Section 4b, 4c, 4d, 4h and 11b; and provided further that such Sublicensee is not then in breach of
its sublicense agreement. 
 f.    Sections 4h, 5b, 5e, 5g, 7, 8, 9, 10, 12, 14, 16e, 16f, 16g, 16h, 17, 19, 21,
23, and 25 will survive any termination or expiration of this Agreement. 
 g.    Any termination of this Agreement
shall not adversely affect any rights or obligations that may have accrued to either party before the date of termination, including without limitation, Company’s obligation to pay all amounts due and payable under Sections 4 (including
any payments required under subsection h thereof), 5 and 11 hereof to the extent accrued prior to termination. 

h.    Upon any termination of this Agreement for any reason other than for Company’s failure to cure a material
breach of this Agreement under Section 16d(ii), Company, Sublicensees, Designees, and their Affiliates have the right, for [***] or such longer period as the parties may reasonably agree, to dispose of Products or substantially completed
Products then on hand, and to complete orders for Products then on hand (the “Inventory”), and royalties shall be paid to Columbia with respect to such Inventory as though this Agreement had not terminated. Within [***] after
termination, the Company shall provide Columbia with an Inventory report. If this Agreement expires under Section 16b, then the Company shall thereafter be free to use the Technical Information, Patents and Materials without any further
obligation to Columbia. 

  
 24 

 i.    Notwithstanding anything to the contrary in the Agreement, to the
extent the manufacture of a Product is Covered By an issued patent within the definition of Patents and occurs before the expiration of such issued patent, the sale of that Product after the expiration date of the issued patent shall still
constitute a royalty-bearing sale under Section 4. 
 17.    Notices. Any notice required or permitted to be given
under this Agreement is sufficient if in writing and shall be considered given (a) when mailed by certified mail (return receipt requested), postage prepaid, or (b) on the date of actual delivery by hand or overnight delivery, with receipt
acknowledged, as follows: 
  

			
	 if to Columbia, to:
	  	 Executive Director
 Columbia Technology
Ventures
 Columbia University
 80 Claremont Avenue, #4F, Mail
Code 9606
 New York, NY 10027-5712

		
	 copy to:
	  	 General Counsel
 Columbia University

412 Low Memorial Library
 535 West 116th Street, Mail Code 4308
 New York, New York 10027

		
	 if to the Company, to:
	  	 Kures, Inc.
 9 Fairlawn Avenue

Dobbs Ferry, New York 10522

 provided, however, except for notices of breach, Columbia may send invoices related to license fees and patent
expenses to the following email address [***], with a copy (which shall not constitute delivery of the invoice) to [***] and [***]; provided, further, except for notices of breach, Columbia may send correspondence related to the Patents in
accordance with Section 11 to the following email address: [***] and [***]; 
 or to such other address as a party may specify by notice hereunder.

 18.    Assignment. This Agreement and all rights and obligations hereunder may not be assigned by either party without
the written consent of the other party. Any attempt to assign without compliance with this provision will be void; provided that upon written notice to Columbia, Company shall have the right to assign this Agreement without such consent to an
Affiliate or in connection with a Change of Control. 
 19.    Waiver and Election of Remedies. The failure of any party
to insist upon strict adherence to any term of this Agreement on any occasion will not be considered a waiver or deprive that party thereafter of the right to insist upon strict adherence to that term or any other term of this Agreement. All waivers
must be in writing and signed by an authorized representative of the party against which such waiver is being sought. The pursuit by either party of any remedy to which it is entitled at any time or continuation of the Agreement despite a breach by
the other will not be deemed an election of remedies or waiver of the right to pursue any other remedies to which it may be entitled. 

  
 25 

 20.    Binding on Successors. This Agreement is binding upon and inures to
the benefit of the parties and their respective successors and assigns to the extent assignment is permitted under this Agreement. 

21.    Independent Contractors. It is the express intention of the parties that the relationship between Columbia and the
Company is that of independent contractors and is not that of agents, partners or joint venturers. Nothing in this Agreement is intended or will be construed to permit or authorize either party to incur or represent that it has the power to incur
any obligation or liability on behalf of the other party. 
 22.    Entire Agreement; Amendment. This Agreement, together
with the Exhibits, sets forth the entire agreement between the parties concerning the subject matter hereof and supersedes all previous agreements, written or oral, concerning such subject matter. This Agreement may be amended only by a written
agreement duly executed by the parties. 
 23.    Severability. If any provision of this Agreement is held by a court of
competent jurisdiction to be unenforceable because it is invalid, illegal or unenforceable, the validity of the remaining provisions will not be affected, and the rights and obligations of the parties will be construed and enforced as if the
Agreement did not contain the particular provisions held to be unenforceable, unless such construction would materially alter the meaning of this Agreement. By way of example, but not by way of limitation, Sections 4h(i), 4h(ii) and 4h(iii) are
intended by Company and Columbia to be severable from each other, such that if one clause is found to be unenforceable, the other clauses remain operative and in effect. 

24.    No Third-Party Beneficiaries. Except as expressly set forth herein, the parties hereto agree that there are no
third-party beneficiaries of any kind to this Agreement. 
 25.    Governing Law. This Agreement is to be governed and
construed in accordance with the internal substantive laws of the State of New York that apply to agreements made and wholly performed within the State of New York and without reference to the conflict or choice of laws principles of any
jurisdiction. Unless otherwise separately agreed in writing, the parties agree that any and all claims arising under or related to this Agreement will be heard and determined only in either the United States District Court for the Southern District
of New York or in the courts of the State of New York located in the City and County of New York, and the parties irrevocably agree to submit themselves to the exclusive and personal jurisdiction of those courts and irrevocably waive any and all
rights that any such party may now or hereafter have to object to such jurisdiction or the convenience of the forum. 

26.    Execution in Counterparts; Facsimile or Electronic Transmission. This Agreement may be executed in counterparts, and
by facsimile or electronic transmission. This Agreement is not binding on the parties until it has been signed below on behalf of each party. 

  
 26 

 IN WITNESS WHEREOF, Columbia and the Company have caused this Agreement to be executed by
their duly authorized representatives as of the day and year that is first written above. 
  

					
	 THE TRUSTEES OF COLUMBIA

UNIVERSITY IN THE CITY OF NEW YORK

			
	By	 	 /s/ [***]
	 	
		 	Executive Director,	 	
		 	[***], AVP	 	
		 	Columbia Technology Ventures	 	
		 	8 June 2020	 	
		 	TTS# [***]	 	

  

			
	KURES, INC.
		
	By	 	/s/ [***]
	Title	 	 CEO

  
 27

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]